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Introduction: Polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune 
myopathy (NAM) form part of the spectrum of idiopathic inflammatory myopathies 
(IIMs). Although the pathogenic mechanisms are different, the unifying feature is that 
of weakness caused, in some way or another, by an inflammatory attack on muscle. 
The mechanism by which weakness develops is still unclear, but experimental animal 
data suggest that dysfunction of the contractile apparatus might contribute to muscle 
weakness in these conditions. This study investigated the contractile function of single 
muscle fibres from patients with IIMs in vitro. Methods: Muscle biopsies obtained from 
patients with IIMs and healthy controls were dissected and chemically permeabilised. 
Single muscle fibres were dissected out and subjected to contractility measurement 
based on standard protocols utilising a permeabilised single fibre system. Specific 
force (SF; maximum force normalised to cross-sectional area), was calculated for each 
fibre and compared between the two groups. In addition, maximum shortening velocity 
and power output were assessed in some of the fibres, and calcium sensitivity in the 
rest. The myosin heavy chain composition of each fibre was determined by means of 
gel electrophoresis. Results: A total of 178 fibres from IIM cases and 174 fibres from 
controls were studied. Specific (normalised) force was 23%, 24% and 29% lower in 
the IIM group for all fibre types combined, type I fibres, and type IIa fibres, respectively. 
Shortening velocity and maximum power output were significantly higher in the IIM 
group for both type I and IIa fibres, compared to controls, while calcium sensitivity was 
higher in type IIa fibres from IIM cases than controls. Discussion: The findings from 
this study suggest that weakness in IIMs may, at least in part, be caused by 
dysfunction of the contractile apparatus leading to impaired contractile force. The 
higher shortening velocity, power output and calcium sensitivity in fibres from IIM 
cases probably represents compensatory mechanisms. Although the mechanism by 
which contractile function is affected has not been investigated, animal studies 
suggest a role for TNF-α. The findings of this study provide a basis for further 








1 PATHOGENIC MECHANISMS OF MUSCLE WEAKNESS IN 
IDIOPATHIC INFLAMMATORY MYOPATHIES: CURRENT CONCEPTS 
___________________________________________________________________ 
 
1.1 Introduction and background 
 Normal skeletal muscle 
 Structure of normal skeletal muscle 
Skeletal muscles are organs that consist of different integrated components, 
namely muscle cells (commonly referred to as muscle fibres due to their cylindrical 
structure), nerve fibres, blood vessels and various layers of connective tissue. The 
connective tissue layers allow a muscle to maintain structural integrity while 
contracting, separate it from surrounding tissues, and compartmentalise the muscle 
fibres within the muscle. Three different connective tissue layers can be identified 
within each muscle (Figure 1), namely the epimysium (surrounds the whole muscle), 
the perimysium (organises the muscle fibres into groups called fascicles), and the 
endomysium (encases individual muscle fibres). 
Muscle fibres are the individual functional units of skeletal muscles. Each fibre 
consists of a sarcolemma (cell membrane) surrounding the sarcoplasm (the cytoplasm 
of muscle cells). Within the cytoplasm are myofibrils, each consisting of strands of 
filaments, arranged into repeating units called sarcomeres (Figure 2). Surrounding 
each myofibril is the sarcoplasmic reticulum (SR), which is the source of intracellular 
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calcium (Ca2+) required for contraction. In order for an action potential to rapidly lead 
to contraction, the sarcolemma is in close contact with the SR by means of 
invaginations called T-tubules. 
 
 
Figure 1. Structural organisation of skeletal muscles.  
(From Wikimedia Commons; https://commons.wikimedia.org) 
 
The sarcomere forms the functional unit of the myofibril and are the units that are 
responsible for the striated appearance of skeletal muscle fibres, which can best be 
seen with electron microscopy (Figure 3). Each sarcomere contains a three-
dimensional arrangement of thick and thin filaments. Thin filaments consist primarily 
of actin, troponin and tropomyosin (visible as the I-band, Figure 3), while thick 
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filaments consist of type II myosin (visible as the A-band, Figure 3). Individual 
sarcomeres are bordered on each side by Z-disks (also called Z-lines), to which actin 
filaments are anchored (figure 4). Other muscle proteins include alpha-actinin (an 
actin-binding protein and major component of the Z-line), titin (which runs from the 
M-line to the Z-line, functions as a molecular spring and is responsible for passive 
force reduction) and costameres, which are regions associated with the sarcolemma 





Figure 2. Structural organisation of individual muscle fibres.  





Figure 3. Electron microscopy image of a part of a myofibril showing sarcomeres with 
its bands and lines.  
(From NIH Centre for Macromolecular Modelling & Bioinformatics; 
http://www.ks.uiuc.edu/~ericlee/Telethonin/; JPEG file: MuscleL1.jpg; accessed 13 March 
2018) 
 
Each myosin molecule contains two heavy chains (MyHC) and four light chains 
(MLC). The heavy chains constitute the tails, which aggregate to form the thick 
filaments, and globular heads, which project off to the sides and are able to bind to the 
myosin binding site situated on the adjacent actin molecules (Figure 4). Two types of 
light chains, regulatory (RLCs) and essential (ELCs, also known as alkali light chains) 
are associated with the globular heads of the MyHCs.1,2 In the resting state, when the 
intracellular Ca2+ concentration is low (pCa2+ = 7.0), the myosin heads are prevented 
from interacting with actin by tropomyosin, which shields the myosin binding site on 
actin. The position of tropomyosin is in turn regulated by troponin, which in effect acts 
as a “lock” to secure tropomyosin in the shielding position.3 
 
 The physiology of muscle fibre contraction 
During muscle contraction, the thin and thick filaments slide over each other, 
leading to shortening of individual sarcomeres.4,5 This leads to shortening of the 
muscle fibres and, therefore, the muscle as a whole. The sliding of thin and thick 
filaments is caused by the interaction between myosin and actin, a process dependent 





Figure 4. Ultrastructure of the sarcomere.  
(From Wikimedia Commons; https://commons.wikimedia.org) 
 
As shown in figure 4, the myosin head contains binding sites for both ATP and 
actin. When ATP binds to myosin, chemical energy is released and ATP is hydrolysed 
into ADP and inorganic phosphate by the myosin ATPase enzyme – the latter forms 
part of the genetic encoding of the MyHC chain. The myosin molecule undergoes a 
conformational change with the head pivoted into an energised position (i.e. chemical 
energy is transformed into mechanical energy), analogous to the cocked hammer of a 
spring-loaded pistol. When actin binds with energised myosin at the actin binding site, 
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and on release of the bound Pi, the stored mechanical energy in the myosin molecule 
is released and the myosin head pivots back to its resting state. This pivoting motion 
causes the myosin and actin filaments to slide over each other, leading to shortening 
of the sarcomere. However, each single pivoting motion of the myosin head results in 
a minute change in shortening of the sarcomere. Therefore, in order to produce the 
large movements required for contraction, the process needs to be repeated. This 
requires detachment of myosin from actin, a process that requires the binding of a new 
molecule of ATP to the myosin ATPase. The newly bound ATP can then be hydrolysed 
and the released chemical energy utilised to regenerate the energised form of myosin.  
In order for contraction to occur in response to a neural stimulus (i.e. to regulate 
contraction), a process termed excitation-contraction coupling is required. The term 
“excitation-contraction coupling” refers to the consolidation of excitation of the 
sarcolemma to actual contraction of the muscle fibre. When the action potential 
spreads along the sarcolemma and T-tubules, membrane depolarization leads to an 
influx of Ca2+ ions via voltage-gated Ca2+ channels, in turn leading to opening of Ca2+ 
channels (ryanodine receptors) in the SR. These Ca2+-induced Ca2+ release channels 
ensure the large and rapid supply of Ca2+ required for contraction.3 The released Ca2+ 
ions attach to binding sites on troponin, leading to a structural change in troponin and 
a resultant altered interaction between troponin and tropomyosin in such a way that 
the myosin binding site on actin is exposed. When this occurs, the myosin-actin cross-
bridges required for contraction can be formed. Muscle contraction ceases when Ca2+ 
is actively pumped back into the SR via sarco/endoplasmic reticulum Ca2+-ATPase 
(SERCA) pumps, returning the tropomyosin to its original form and shielding the 
myosin binding sites on actin.3 
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 Muscle fibre types 
Muscle fibres can be classified into different types based on the myosin ATPase 
activity at different pHs or antibodies directed at the various MyHC isoforms. Both 
histological classifications correlates well with the isoform protein concentration 
determined from biochemical techniques. Three main types can be distinguished, 
namely type 1 (slow twitch oxidative; MyHC-I), type 2A (fast twitch oxidative glycolytic; 
MyHC-IIa) and type 2B (fast twitch glycolytic; MyHC-IIx).6 Because of the MyHC 
composition, type 1, 2A and 2B are usually referred to as type I, IIA and IIX, 
respectively, and this nomenclature will be used in this thesis. Additionally, Smerdu et 
al. (1994) has shown that type IIB fibres have been misclassified as they contain 
transcripts of MHC IIx and not MHC IIb.7 By convention, upper case is used where 
immunohistochemical techniques are employed for typing (e.g. type IIA), and lower 
case where fibre types are identified by gel electrophoresis (e.g. type IIa). A fourth 
type, MyHC-IIb, is expressed in murine, but not human skeletal muscle.8 A fifth type 
(embryonic; MyHC-emb) can also be identified, mainly in regenerating fibres, as can 
be seen in muscle disorders such as muscular dystrophies.9 Fibres with combinations 
of MyHC isoforms (so-called hybrid fibres) can also be identified in biopsies.  
Table 1 summarises the main composition, histochemical and mechanical properties 




 Muscle fibre type 
 I IIA IIX 
MyHC composition MyHC I MyHC II MyHC X 
Histochemical properties    
   Myosin ATPase staining intensity  at pH 10.3 Low High High 
   Myosin ATPase staining intensity  at pH 4.6 High Low Medium 
   Oxidative enzyme activity (SDH, CS, 3HAD, 
NADH, COX) 
High Medium Low 
Glycolytic capacity (LDH, PFK) Low Medium High 
Triglyceride content High Medium Low 
   Glycogen content Low High Medium 
Mechanical properties    
   Twitch contraction time (shortening velocity) Slow Fast Fast 
   Maximum tetanic force Small Moderate High 
   Fatigue resistance Very high Moderate/High Low 
 
Table 1. Features of the different muscle fibre types. 
MyHC: myosin heavy chain; NADH: nicotinamide adenine dinucleotide, reduced; PAS: 
periodic acid Schiff; SDH: succinate dehydrogenase, CS: citrate synthase; 3HAD: 3-
hydroxyacetyl co A dehydrogenase; LDH: lactate dehydrogenase; PFK: 
Phosphofructokinase. (Adapted from Karpati et al.6) 
 
 Normal muscle fibre type proportion and size 
In humans, reliable data for fibre type proportion and size are only available for 
the Vastus lateralis (VL) muscle. A meta-analysis of 18 studies estimated type I fibre 
proportion (± SD) in the VL to be 50.3 ± 1.9%, with no significant difference between 
men and women.10 The same meta-analysis provided estimates for cross-sectional 
area (CSA) per fibre type in men and women; the means and pooled SDs per gender 
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and fibre type are provided in Table 2. It is interesting to note that this meta-analysis 
found type 1 fibres to be larger than type 2 fibres. However, a different paper reviewing 
data including 87 individuals (both men and women) from three different studies found 
the converse, type 1 and 2 fibre sizes being 4 754 ± 1 137 µm2 and 5 145 ± 1 329 µm2, 
respectively.11 This underlines the fact that muscle fibre sizes appear to be extremely 
variable across different studies. 
 
 Muscle fibre type 
 I IIA IIX 
Men (n=141) 4 652 ± 1 391 4 167 ± 1 630 3 697 ± 1 577 
Women (n=125) 3 840 ± 1 587 3 056 ± 1 598 2 033 ± 1 519 
 
Table 2. Mean CSA (µm2) ± SD for different muscle fibre types in men and women, 
reproduced from a meta-analysis by Gouzi et al. (2013).10 
CSA: cross-sectional area; SD: standard deviation. 
 
It is interesting to note the effect of immobilisation, on the one hand, and training 
on the other, on muscle fibre size. During periods of immobilisation, the size of both 
type I and II fibres decrease significantly.12,13 Resistance training leads to an increase 
in size of both fibre types,14,15 while pure endurance training may lead to a decrease 
in size of both fibre types.16 However, despite the decrease in size, force remains 
unchanged or even increases in response to endurance training, resulting in an 
increase in specific force (SF; maximum force normalised to cross-sectional area). 
This underlines the fact that contractile force is not directly proportional to fibre size, 
and may have important implications for understanding adaptation of muscle fibres to 
other factors, such as disease. 
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 Muscle Disorders 
Muscle disorders (myopathies) in adults arise from a wide variety of hereditary 
and acquired aetiologies, and may be due to abnormalities in structural proteins (e.g. 
muscular dystrophies, critical illness myopathy), impaired metabolic pathways (e.g. 
disorders of carbohydrate, lipid or mitochondrial metabolism) or immune-mediated 
inflammation (e.g. idiopathic inflammatory myopathies). Although the aetiologies are 
heterogeneous, the unifying feature is that of muscle weakness that affects 
predominantly large proximal and axial muscle groups.  
 
Theoretically, the force generated by a muscle is directly related to the number 
and firing frequency of recruited muscle fibres and the contractile force generated by 
each of the individual fibres.17 Therefore, weakness, defined as a subjective (reported 
by an individual) or objective (found on clinical examination) impression of lack of 
strength, may result from either quantitative (decrease in the number of functional 
fibres) or qualitative (impaired contraction of individual fibres) factors (Figure 5). 
Disease processes that may lead to a decrease in the number of functional fibres 
include myofibre necrosis (due to inflammation, toxins etc.), impaired neuromuscular 
junction transmission (e.g. myasthenia gravis), and inexcitability of the sarcolemma 
(e.g. critical illness myopathy, ion channel disorders). Factors that may lead to 
impaired contractile function of individual fibres include structural abnormalities of 
proteins (e.g. muscular dystrophy), myofibrillary dysfunction, deficient cellular energy 
production (e.g. mitochondrial disorders, glycogen storage disorders etc.) and 








Several hereditary myopathies are caused by mutations in genes coding for 
structural muscle proteins, e.g. dystrophinopathies, sarcoglycanopathies. Abnormal or 
dysfunctional structural proteins could theoretically lead to impaired contractility of 
muscle fibres, as has been shown to occur (although not conclusively) in some forms 
of muscular dystrophy.18-20 As the disease progresses, loss of muscle fibres most likely 
contributes to the weakness, and is probably the reason for the progressive nature of 
these disorders.  
In contrast to disorders affecting structural muscle proteins, the mechanism of 
weakness in acquired muscle disorders is less obvious. The most prevalent group of 
acquired muscle disorders is that of the idiopathic inflammatory myopathies (IIMs). 
The group of IIMs consists of polymyositis (PM), dermatomyositis (DM), inclusion body 





Decreased number of 
contracting fibres 











Dysfunction of individual 
fibres 
 
Figure 5. Potential pathogenic processes in muscles leading to muscle weakness. 
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include a group called non-specific inflammatory myopathy (NIM). Although IBM is 
also characterised by an inflammatory component, it differs from the other disorders 
in the group both from a clinical and pathogenic perspective. The distinguishing clinical 
characteristics include age of onset in the sixth decade or later, prominent finger flexor 
and pharyngeal weakness, slow onset and progression over years, delayed diagnosis 
(mean 5.2 years from onset of symptoms),21 and only moderately raised serum CK,22 
while the pathogenesis is characterised by the presence of a prominent degenerative 
component.23,24 IBM will, for these reasons, not be included in the remainder of the 
discussion. 
IIMs are rare disorders, with an annual incidence of between 1.2 and 19 per 
million person-years.25 These disorders affect individuals of all ages, and usually 
present as a subacute onset of symmetric proximal and axial weakness and fatigue 
(defined as a subjective sensation of fatigue and not an objective change in 
performance).26-28 In the case of DM, characteristic skin involvement consisting of 
Gotron’s papules, heliotrope rash, a shawl sign or a V-sign, may be present. On 
muscle biopsy, necrotic fibres, inflammatory cell infiltrates, major histocompatibility 
class I  (MHC-I) antigen expression, and muscle fibre atrophy can be seen.29 Table 3 
summarises the currently accepted diagnostic criteria for the different entities 
comprising IIMs. 
Although different entities are recognised within the group of IIMs, the 
classification of IIMs is not universally agreed upon.30 Despite the fact that different 
pathological features and mechanisms are recognised for the respective entities, the 
similarities between them may perhaps overshadow the differences. These include (1) 
symmetrical proximal and axial weakness, (2) subacute course, (3) elevated serum 
muscle enzymes (creatine kinase) (4) inflammation, necrosis, and regeneration on 
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muscle histology, (5) myopathic features and “irritable” phenomena on 
electrophysiological examination (spontaneous activity on needle EMG examination 
indicating muscle fibre necrosis), and (6) responsiveness to immunosuppressive 
therapy. It could therefore be argued that, although accomplished through different 
pathogenic mechanisms, the unifying feature is that of weakness caused, in some way 
or another, by an inflammatory attack on muscle. 
Of particular relevance to this research are the immunological processes at play 
in muscle in IIMs, as these processes are critical in explaining the resultant weakness 
and fatigue. In DM, C5b-9 membrane attack complex (MAC) is activated early and 
deposited on the endothelial cells. The activation of MAC leads to the release of 
proinflammatory cytokines and facilitates the migration of activated lymphocytes (B 
cells, CD4+ T cells and plasmacytoid dendritic cells), to the perimysial and endomysial 
regions. PM, by contrast, is due to a MHC-I-restricted, cytotoxic T cell-mediated 
destruction of muscle fibres, while an antibody-dependent complement-mediated lysis 
is most likely responsible in NAM.26,31-33 However, despite differences in 
immunopathogenesis, a number of overlapping characteristics can be identified 
across all subtypes of IIMs. These include expression of MHC-I molecules on the 
surfaces of muscle fibres, as well as the presence of a number of pro-inflammatory 
cytokines, in particular interleukins (ILs), type I interferons (IFNs), and tumour necrosis 
factor-alpha (TNF-α).34,35 The possibility that one or more of these cytokines could 
cause or contribute to weakness should be considered, and will be explored below. 
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Skin rash or 
calcinosis# 
Present Absent Absent Absent Absent 
*Myopathic muscle weakness, affecting proximal muscles more than distal ones and sparing eye and facial muscles, is characterised 
by a subacute onset (weeks to months) and rapid progression in patients who have no family history of neuromuscular disease, no 
exposure to myotoxic drugs or toxins, and no signs of biochemical muscle disease. 
#Calcium deposits in the skin 
 
Table 3. Diagnostic criteria for inflammatory myopathies. From Dalakas, Liang26,36 
1.2 Synopsis of current literature 
Most research on the pathogenic mechanisms of IIMs has focussed on the 
induction and maintenance of the inflammatory response, as well as the processes 
involved in immune-mediated muscle fibre necrosis. It is important to note that the focus 
on inflammatory necrosis of myofibres is based on the assumption that this phenomenon 
explains the weakness observed in these conditions. However, there is reason to believe 
that at least some of the observed muscle weakness is due to dysfunction of viable 
muscle fibres. The literature review will provide an overview of the potential mechanisms 
involved in the development of muscle weakness. 
 
 Muscle fibre necrosis 
Weakness in IIMs is usually attributed to loss of muscle fibres due to inflammatory 
necrosis. However, there are a number of limitations that need to be considered before 
attributing weakness solely to loss of muscle fibres in these conditions. Firstly, there is 
poor correlation between the degree of inflammation and muscle weakness, and muscle 
weakness may in fact develop before the inflammatory infiltrate is present on muscle 
biopsy.37 Secondly, the number of necrotic fibres observed on histological analysis is 
usually small. Very little quantitative data on fibre necrosis is available, and the presence 
of necrotic fibres is often described as “scattered”.29,35,38 A single study quantified the 
presence of necrotic fibres in 13 patients with DM and 15 with PM, and found a mean of 
~1% of fibres to be necrotic (range from 0-3%).39 Thirdly, there is typically a clear-cut 
improvement in strength following treatment with corticosteroids, often becoming evident 
within 3-4 weeks.35,38 It is unlikely that improvement in strength is due to restitution of 
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muscle fibre numbers, since muscle fibres are post-mitotic, and do not divide to form new 
fibres. An alternative explanation for the increase in strength due to corticosteroid 
treatment is hypertrophy of existing fibres. However, this argument is potentially negated 
by the fact that the histological hallmark of chronic treatment with corticosteroids is in fact 
type II fibre atrophy (with no or little change in type I fibres) and not hypertrophy.40  Given 
the considerable difficulties that are raised when attributing muscle weakness to muscle 
fibre necrosis, it is highly likely that one or more different explanations exist. 
 
 Structural or functional abnormalities of contractile apparatus  
Exogenous TNF-α has been shown to decrease contractile force in diaphragmatic 
and limb muscles in animal models.41-44 Weakness develops within hours of 
administration (i.e. too early to be explained by muscle fibre atrophy and necrosis), and 
is induced by TNF-α levels that are too low to cause muscle atrophy. In addition, MHC-I 
upregulation appears to be related to reduced force-generating capacity in slow-twitch 
muscle of mice.45 
A single study evaluating in vitro single muscle fibre function in untreated DM and 
IBM has been performed.46 Five patients in each group were included, and compared 
with healthy controls. No differences in force generation between the two groups could 
be shown, and it was proposed that the force generating capacity of the remaining 
(surviving) muscle fibres are preserved in DM and IBM. However, this study had a number 
of shortcomings that could have influenced the results and  will be discussed in Chapter 
2. Therefore, muscle fibre contractility in IIMs remains largely unexplored.  
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 Metabolic abnormalities in muscle 
 
Although it is generally assumed that autoimmune and inflammatory processes are 
central to the muscle weakness in IIMs, a number of observations would suggest that 
non-immune mechanisms may contribute to the weakness. For example, there are 
dissociations between the degree of inflammation and weakness,47,48 a subgroup of 
myositis patients do not respond to corticosteroids,49 and in some patients, corticosteroid 
treatment leads to elimination of the inflammatory infiltrate from the muscle tissue with 
little or no improvement in strength.50 One of the proposed metabolic defects in IIMs is an 
acquired deficiency of the enzyme AMP deaminase 1 (AMPD1, also known as 
myoadenylate deaminase), a rate-limiting enzyme in the purine cycle, and an important 
component of cellular energy production. In a mouse model of IIM, Coley et al. illustrated 
a significant reduction in AMPD1 mRNA, protein expression and enzyme activity.37 Of 
further significance was the fact that the loss of enzyme activity and weakness appeared 
prior to the inflammatory infiltrate. These findings support the notion that weakness in 
IIMs may be due (at least partly) to metabolic factors and not only to inflammatory muscle 
damage. What is responsible for the deficiency in AMPD1 is not clear, but it is theoretically 
possible that cytokines may modulate AMPD1 expression in muscle. It has further been 
shown that IFNs and IL-1 are able to inhibit the expression of AMPD1 in vitro, and that 
IL-15 may have a stimulatory effect on the expression of AMPD1.51 However, it should be 
noted that the clinical relevance of AMPD1 deficiency, whether inherited or acquired, is 




 Effect of corticosteroids on muscle 
Corticosteroids are the most effective anti-inflammatory drugs available for the 
treatment of chronic inflammatory conditions, including the IIMs, and examining the 
effects of this medication on the inflammatory response in muscle tissue may provide 
valuable indirect insights into the pathogenic mechanisms. Down-regulation of 
inflammatory gene expression encoding multiple inflammatory proteins (e.g. cytokines, 
chemokines etc.) is the most important anti-inflammatory effect of this group of drugs.53 
In muscle biopsies of IIM patients treated with corticosteroids, there is decreased 
expression of particular cytokines, including IL-1α and IL-1β.50 As noted above, IL-1 may 
inhibit the expression of AMPD1, and corticosteroids may therefore indirectly increase the 
expression of AMPD1 through this mechanism. Corticosteroids also inhibit the secretion 
of TNF by monocytes,54 and also decrease serum levels of soluble TNF-α receptors 
(TNFR1 and TNFR2) in other autoimmune diseases.55  
However, corticosteroids may have other non-immune effects on muscle. The 
effectiveness of corticosteroids in the treatment of Duchenne muscular dystrophy, an 
inherited muscle disorder due to mutations in the gene coding for dystrophin, illustrates 
this well. A number of hypotheses about the mechanism of action in this condition have 
been put forward and include a positive effect on myogenesis,56,57 an anabolic effect on 
muscle (resulting in increased muscle mass),58 and an increase in resting intracellular 
Ca2+ concentration.59 Whether any of these mechanisms are important in IIMs remains to 
be explored.  
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 Summary of literature 
In addition to inflammatory necrosis of muscle fibres, other effects on muscle, both 
inflammatory and non-inflammatory, may contribute significantly to weakness in IIMs. 
Contractility of muscle fibres in IIMs has not adequately been explored, although a 
number of observations would suggest that dysfunction of the contractile apparatus might 
contribute to muscle weakness in these conditions. These include an acquired deficiency 
of AMPD1, depression of muscle fibre contractility by TNF-α, a rapid response to 
treatment with corticosteroids, and dissociation between the degree of inflammation and 
weakness.   
It therefore appears unlikely that a decrease in the number of muscle fibres due to 
inflammatory necrosis is the sole mechanism responsible for weakness in IIMs, and it is 
probable that qualitative changes in muscle fibre contractility play an important role. 
These factors have not been adequately explored, and warrant careful investigation.  
 
1.3 Aims and objectives 
Central to an investigation into the possible mechanisms involved in the 
development of weakness in IIMs, is a better understanding of the effect of inflammatory 
muscle disease on the functional integrity of the contractile apparatus of the muscle fibre. 
This research project set out to achieve this by means of the following objectives: 
i. Morphological and metabolic assessment of muscle tissue from patients with IIMs. 
Morphological assessment included quantification of the presence of necrotic muscle 
fibres, (2) fibre size and (3) fibre type, while metabolic function was investigated by 
means of enzyme analysis. 
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ii. Assessment of the maximum absolute and normalized (specific) force generated by 
single muscle fibres from patients with untreated IIMs compared to healthy volunteers. 
iii. Assessment of the maximum velocity and power generation ability of single muscle 
fibres from patients with untreated IIMs compared to healthy volunteers. 
iv. Assessment of the Ca2+ sensitivity of single muscle fibres from patients with untreated 
IIMs compared to healthy volunteers. 
 
1.4 Hypothesis 
The hypothesis is that weakness in IIMs is related not only to a decrease in the 
number of muscle fibres (i.e. a structural abnormality due to inflammatory necrosis), but 
also to abnormalities of the contractile properties of the individual muscle fibres (i.e. a 
functional abnormality). These abnormalities may manifest as one or more of the 
following: 
i. Impaired generation of maximum SF of individual muscle fibres. 
ii. Alterations of contractile velocity and power output of individual muscle fibres. In the 
face of impaired force generation, it is expected that there would be a compensatory 
increase in maximum shortening velocity of muscle fibres in order to maintain power 
output. 





In addition to inflammatory necrosis of muscle fibres, other effects on muscle, both 
inflammatory and non-inflammatory, may contribute significantly to weakness in IIMs. 
Contractility of muscle fibres in IIMs has not adequately been explored, although a 
number of observations would suggest that dysfunction of the contractile apparatus might 
contribute to muscle weakness in these conditions. These include an acquired deficiency 
of AMPD1, depression of muscle fibre contractility by TNF-α, a rapid response to 
treatment with corticosteroids, and dissociation between the degree of inflammation and 
weakness.   
It therefore appears unlikely that a decrease in the number of muscle fibres due to 
inflammatory necrosis is the sole mechanism responsible for weakness in IIMs, and it is 
probable that qualitative changes in muscle fibre contractility play an important role. 
These factors have not been adequately explored, and warrant careful investigation. It is 
important to note that the study was designed to investigate whether the contractility of 
structurally intact (i.e. non-necrotic) muscle fibres is affected in patients with IIMs, and not 
to determine what the reason for impaired contractility (if present) is. This could form the 





2 QUANTITATIVE ANALYSIS OF MORPHOLOGIC AND METABOLIC 
CHARACTERISTICS OF MUSCLE BIOPSIES FROM PATIENTS WITH 
IDIOPATHIC INFLAMMATORY MYOPATHIES 
______________________________________________________________________ 
 
2.1 Introduction and synopsis of current literature 
The diagnosis and classification of the IIMs is heavily dependent on the 
morphological features displayed on muscle histology, and the qualitative histological 
features of the IIMs have been extensively examined and documented. In DM, these 
features include a perivascular inflammatory infiltrate consisting of predominantly CD4+ 
T helper cells, perifascicular atrophy, major histocompatibility complex class I (MHC-I) 
antigen expression in the perifascicular regions, and the presence of scattered necrotic 
and regenerating muscle fibres.29,60 In PM, the typical findings include an endomysial and 
perimysial inflammatory infiltrate consisting of predominantly cytotoxic CD8+ T cells, 
widespread MHC-I antigen expression, the invasion of non-necrotic muscle fibres by 
CD8+ lymphocytes, and scattered necrotic and regenerating muscle fibres.29,60 NAM is 
characterised by randomly distributed necrotic muscle fibres and regenerating fibres, little 
or no inflammatory infiltrate, and weak or no MHC-I expression.29,60 In contrast, there is 
a paucity of quantitative histological data in IIMs. For example, the number of necrotic 
fibres on muscle biopsy specimens from patients with DM and PM has only been 
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documented in a single study.39 Very little quantitative data on muscle fibre size or fibre 
type proportion is available. A single paper described mean fibre diameters in IIMs, but a 
detailed description of the methodology (in particular whether smallest or largest 
diameters were measured) was not provided, and comparison to a healthy control group 
was not made.61 In both clinical practice and research, reporting of these parameters is 
generally limited to subjective descriptions. Although such an approach is unlikely to 
affect the overall validity of the histological interpretation, it could be argued that 
quantitative data may provide more useful information on the underlying pathogenic 
mechanism of these disorders. For example, if fibre type proportion is found to be altered 
in IIMs, this may indicate an increased vulnerability to inflammatory necrosis or impaired 
regenerative capacity of one fibre type. 
In addition to morphological features of the IIMs, data on the metabolic function of muscle 
fibres may provide useful insights into the capacity of affected muscles to generate and 
maintain force production. A few studies have investigated mitochondrial function in DM 
and /or PM by means of enzyme histochemistry, biochemical assays, or both.62-65 Enzyme 
histochemistry, utilising cytochrome c oxidase (COX) and succinate dehydrogenase 
(SDH) reactions, revealed features suggestive of electron transport chain (ETC) 
abnormalities in most cases, but results of biochemical analysis were less consistent, with 
not all studies confirming ETC abnormalities. Proteomic analysis was performed in one 
of these studies, and revealed down-regulation of electron transport chain (ETC) 
subunits, assembly factors, and tricarboxylic acid (TCA) cycle enzymes.63  Another study 
evaluated citrate synthase (CS), a mitochondrial matrix enzyme involved in the Krebs 
cycle, and 3-hydroxyacyl-CoA dehydrogenase (3-HAD), an enzyme involved in 
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mitochondrial beta-oxidation, in patients with PM and DM before and after a 12-week 
endurance training program.66 The investigators found a significant increase in enzyme 
activity after the training program. 
 
2.2 Purpose of the study 
 Aims and objectives 
The aims of the study were to determine whether there are morphological and/or 
biochemical abnormalities present in muscle of patients with IIMs that could (at least in 
part) explain the weakness and fatigue that patients with these disorders experience. In 
order to achieve this, the objectives of the study were: 
i. To determine the mean CSA of each muscle fibre type in muscle from patients with 
IIMs and compare it to healthy controls. 
ii. To determine the fibre type proportion in muscle from patients with IIMs and compare 
it to healthy controls. 
iii. To measure the activities of enzymes involved in different metabolic pathways in 
muscle from patients and compare it to healthy controls. 
iv. To quantify the amount of necrosis present in muscle from patients with IIMs 
 
  Hypotheses 
It is hypothesized that the mean CSA of all fibre types is decreased in IIMs, but that 
fibre type proportion is unaffected. Furthermore, based on previous data suggesting 
abnormalities in the electron transport chain, as well as the reported early fatigue in 
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patients with IIMs, it is hypothesized that enzyme analyses would reveal the presence of 
metabolic abnormalities. In addition, based on limited data,39 it is hypothesized that 
quantitative analysis will reveal a relatively low number of necrotic fibres in muscle 
biopsies from IIM cases. 
 
2.3 Methods 
 Sources of muscle biopsy specimens 
  Cases 
Participants were recruited from the in- and outpatient departments of the Divisions 
of Neurology and General Medicine, Tygerberg Hospital. Only patients who were to 
undergo diagnostic muscle biopsies were asked to participate. All adult patients in 
Tygerberg Hospital possibly requiring diagnostic muscle biopsies are referred to the 
Division of Neurology for assessment, and all diagnostic muscle biopsies are performed 
in the Division of Neurology by or under supervision of the principal investigator. Following 
informed consent, the muscle specimens for study purposes were obtained during the 
biopsy done for diagnostic purposes, and no biopsies were done for the sole purpose of 
this study. Modified Rankin Scale (MRS) assessment (Table 4), as a marker of disability, 
was done at the time of the muscle biopsy. 
Patients meeting the following criteria were included: 
i. Age 18 years or older. 
ii. A diagnosis of PM, DM, or NAM. 
Note: because a diagnostic muscle biopsy is necessary for confirming the 
diagnosis, definitive diagnoses were not available at the time of the biopsy. Therefore, 
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muscle tissue was obtained from all patients with a likely diagnosis of one of above, but 
only tissue from participants in whom the diagnosis has been confirmed were further 
assessed (immunohistochemistry, enzyme analysis and contractility studies were 
postponed until a definitive diagnosis had been made). The final diagnoses were based 
on accepted clinical, laboratory, electromyographic and histological criteria (as discussed 
in Chapter 1) and a response to treatment with corticosteroids at 6 weeks after treatment 
initiation. IBM cases were excluded from the study, as IBM differs significantly from the 
other IIMs in terms of pathogenesis (prominent degenerative component), course (slowly 
progressive), time to diagnosis (mean 5.2 years), and response to treatment.21,23,24 
Patients with any of the following were excluded: 
i. Recent treatment with intravenous immunoglobulin, plasmapheresis or corticosteroids 
(within the previous 6 weeks before the biopsy) or steroid-sparing agents (within the 
previous 6 months before the biopsy). 
ii. Treatment with oral anticoagulants (e.g. warfarin), as this is a contra-indication to 
performing a muscle biopsy. 
iii. The presence of any other neurological or muscle disorder, as these may potentially 




0 No symptoms at all 
1 No significant disability despite symptoms; able to carry out all usual 
duties and activities 
2 Slight disability; unable to carry out all previous activities, but able to look 
after own affairs without assistance 
3 Moderate disability; requiring some help, but able to walk without 
assistance 
4 Moderately severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5 Severe disability; bedridden, incontinent and requiring constant nursing 
care and attention 
6 Dead 
 
Table 4. The Modified Rankin Scale. 
 
 Controls 
Controls were healthy adults (older than 18 years), male or female, and from all 
ethnic groups, who were volunteers participating in approved studies within the UCT/MRC 
Research Unit for Exercise Science and Sports Medicine (ESSM). Their muscle samples 
served as a comparison for the diseased muscle for enzyme analysis. These individuals 
were informed about this additional research study and assured that the donation of a 
small part of their biopsy would not affect the overall outcome of the study in which they 
were currently participating. A separate information sheet and consent form were 
provided for this purpose. We attempted to match healthy volunteers to cases for both 
age and sex as closely as possible. For comparison of morphometric data (fibre type 
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proportion and CSA), we utilized published reference values (see section on Statistical 
analysis). 
 
 Specimen acquisition and storage 
 Cases 
The muscle samples for study purposes were obtained from the muscle tissue 
acquired for diagnostic purposes. Biopsies were performed by the investigator under local 
anaesthesia using standard techniques for an open biopsy. Measurement of the 
contractile properties of single muscle fibres requires only a small sample of tissue, which 
can be obtained by needle biopsy. However, to ensure the acquisition of sufficient tissue 
for diagnostic purposes, open biopsies and not needle biopsies are preferred and is 
standard practice in most centres worldwide. All biopsies were taken from the vastus 
lateralis muscle via an incision 2-3 centimetres anterior to the midpoint of a line 
connecting the greater trochanter and the superior margin of the patella.  
Fresh muscle specimens were divided into 2-3 samples of approximately 6mm x 
4mm x 4mm, rapidly frozen in liquid nitrogen and stored at -200°C until analysis.  
 
 Controls 
Muscle samples were obtained from the vastus lateralis of participants by means 
of a Bergström needle biopsy under local anaesthesia. Access to the muscle was gained 
via an incision at the same site as those used for open biopsy in controls (2-3 centimetres 
anterior to the midpoint of a line connecting the greater trochanter and the superior margin 
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of the patella). One to three samples of approximately 4mm x 4mm x 4mm were obtained, 
rapidly frozen in liquid nitrogen and stored at -200°C until analysis. 
 
  Preparation and analysis 
 Morphometric analyses (fibre typing and CSA) of muscle from IIM cases 
Fibre type and CSA were determined by means of fluorometric 
immunohistochemistry. Serial sections of 10 µm thickness were cut at -22°C using a Leica 
CM1100 cryostat. The sections were mounted on glass slides and allowed to dry at room 
temperature for one hour, after which they were stored at -20°C overnight until further 
processing. Slides were blocked with 5% bovine serum albumin (BSA) for 1 hour in a 
humidifying box at room temperature, and then incubated overnight at 4°C with primary 
antibodies against MyHC I (BA-D5), MyHC IIA (SC71) and MyHC IIX (6H1), all three at a 
concentration of 1:50. These antibodies were obtained form Developmental Studies 
Hybrydoma Bank (DSHB, Iowa, USA). Following incubation, slides were washed twice 
with 0.15M phosphate buffered saline (PBS) and then incubated for 2 hours at room 
temperature with fluorescent-tagged secondary antibodies (AMCA goat anti-mouse 
IgG2b and AlexaFluor 488 goat anti-mouse IgG1; Jackson Immunoresearch 
Laboratories, Pennsylvania, USA). After incubation, slides were washed and mounted 
with fluorescent mounting media (Mowiol), and left overnight in the dark at room 
temperature. Slides were viewed with a Nikon Eclipse i80 fluorescent microscope and 
images were captured for analysis at 100x magnification with a Canon EOS 650D digital 
camera.  
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During image analysis, fibres were classified as type I, IIA, IIX, I/IIA hybrid, I/IIX 
hybrid or IIA/IIX hybrid (Figure 6) based on colour differentiation according to the 
fluorescent-tagged secondary antibody, and the fibre type proportion was calculated for 
each of the IIM specimens. After typing, the circumference (C), expressed in µm, of each 
fibre was measured and CSA, expressed as µm2, calculated using ImageJ pre-calibrated 
software (NIH, Bethesda, Maryland, USA). All fibres in each captured image were 
included in fibre type proportion calculation, but only type I, type IIA and type IIX fibres 
were included in CSA analysis, due to the paucity of comparative data in the literature. 
For CSA analysis, all fibres of each type (I, IIA and IIX) in each biopsy, up to a maximum 
of 40 fibres per type per biopsy, were measured. Care was taken to measure only cross-
sectional and not longitudinally oriented fibres. Mean CSA was calculated per fibre type 





Figure 6. (A) H&E stained frozen section of muscle from a patient with necrotising 
autoimmune myopathy (NAM) showing myofibre necrosis (asterisk). (B) Example of 
images obtained by fluorometric immunohistochemistry of 10 µm thickness sections of 
muscle.  
For illustrative purposes, only parts of the images are shown. The images illustrate type I fibres 
(blue), type IIA fibres (green) and type IIX fibres (red). Orange or green/red combined fibres 
represent type IIA/IIX hybrid fibres, while purple or blue/red combined fibres (not shown) 
represent type I/IIX hybrid fibres. 
 
 Enzyme activities 
Lactate dehydrogenase (LDH), 3-hydroxyacyl-CoA dehydrogenase (3-HAD), citrate 
synthase (CS) and phosphofructokinase (PFK) maximal activities were determined using 
the fluorometric methods described by Essen-Gustavsson et al. (1984) and Kohn et al. 
(2007).67,68 First, a muscle sample from each participant (each with a wet weight of ± 40 
mg) was freeze-dried over night at -50°C under vacuum. 0.1 M potassium phosphate 
homogenising buffer (pH 7.3) was then added to a small portion of the freeze-dried 









was pulse-sonicated on ice for three sessions of ten seconds each. The total protein 
concentration of each homogenate was determined using the Bradford protein assay.69 
A BSA stock solution was used to produce a series of standard BSA solutions with 
concentrations ranging from 0.0 – 0.5 g/l, which were pipetted into wells of a 96-well 
microplate and Bradford reagent added. A volume of 10 µl of each muscle homogenate 
was then pipetted in duplicate into separate wells of the microplate and 250 µl Bradford 
reagent added to each well. After incubation for 5 minutes at room temperature, the 
spectrometric absorbance was measured at 595 nm. A standard protein curve was 
constructed from the known BSA concentrations and fitted with a linear equation, which 
was utilised to calculate the protein concentration of each muscle homogenate.  
Next, an NADH standard curve was generated by measuring the fluorescence of 
different known concentrations of NADH (excitation wavelength 340 nm; emission 
wavelength 460 nm), and the slope determined (fluorescence/µM NADH). Finally, 
enzyme activities in the muscle homogenates were determined by recording the emission 
at 460 nm for 5 minutes with 30-second intervals, using an excitation wavelength of 340 
nm. A volume of 250 µl of the enzyme reagent was used for all assays; sample volumes 
were 3 µl for the LDH assay and 5 µl for the 3-HAD, CS and PFK assays. All enzyme 
activities were expressed as μmol/min/g protein. 
 
  Quantification of muscle fibre necrosis 
For quantification of muscle fibre necrosis, either haematoxylin and eosin (H & E) 
or Gomori trichrome stained frozen sections (1 per IIM case) were analysed. Each slide 
was photographed, and all fibres in each captured image were counted. Thereafter, the 
 44 
number of necrotic fibres in each image was determined, and confirmed by a qualified 
neuropathologist (Dr D Zaharie, EFN). The percentage of necrotic fibres for each IIM 
case, as well as the mean percentage of necrotic fibres, was subsequently calculated. 
 
  Statistical analyses 
For comparison of morphometric data, we used published reference values from a 
meta-analysis rather than our own control data. Since published values on muscle fibre 
size appears to be highly variable (see Chapter 1), data from a large meta-analysis would 
provide better reference values than a limited number of controls from a single centre. 
For analysis of enzyme activities, we compared enzyme activities in muscle homogenates 
from IIM cases and controls. 
Statistical analysis was performed using Graphpad Prism version 7 (GraphPad 
Software, La Jolla California USA). ). For all parameters, mean ± SD was calculated, 
unless stated otherwise. Variables were compared using the Mann-Whitney U test for 
non-parametric data. Statistical significance was set at P < 0.05. 
 
2.4 Results 
Participants in the study consisted of six healthy controls (two male, four female) 
and five patients with IIMs (all female). The IIM group consisted of one patient with PM, 





 IIMs CONTROLS 
Age 48 (26-60) 30 (22-44) 
Gender 5F 2M, 4F 
Diagnosis 1 PM, 2 DM, 2 NAM Healthy, recreationally active 
Modified Rankin Scale 3 (1-5) 0 
 
Table 5. Participant details. Age is reported as mean (range) in years. Modified Rankin 
Scale is reported as median (range). By definition, the MRS of all controls were 0 (no 
symptoms). 




  Fibre type proportion and CSA 
Morphometric analysis of IIM specimens revealed a mean type I fibre proportion of 
36 ± 16%. This was substantially lower than published reference values for women (mean 
48.1 ± 2.6%),10 as well as previously published summary data from 90 controls (men and 
women; 87 historical).11 However, the mean type I proportion ranged from 18 – 61% in 
the 5 IIM cases, suggesting significant differences within the group (Figure 7). This 
observation is further supported by the relatively large SD, indicating a wide distribution 




Figure 7. Fibre type proportions (%) for each IIM case. 
DM: Dermatomyositis; NAM: Necrotising autoimmune myopathy; PM: Polymyositis. 
 
 
CSA analysis did not reveal a decrease in fibre size in IIM cases (Table 6). In fact, 
mean CSA was higher than published reference values for women for all three fibre 
types,10 but similar to other published data that included predominantly men.11 Only the 




Cross-sectional area (µm2) 
 I IIA IIX 
IIM cases 5 397 ± 2 779 5750 ± 3566 6726 ± 3163 
   All type II combined  5 621 ± 3 290 
Published reference values: women 
(Gouzi 2013)10  
3 840 ± 1 587 3 056 ± 1 598 2 033 ± 1 519* 
Published data: men and women 
(Henning, 2017)11 
4 754 ± 1 137 5,145 ± 1,329 
 
Table 6. Cross-sectional area (CSA) for the vastus lateralis muscle in IIM cases and 
healthy controls.  
Values provided are means ± SD. The study by Henning et al. (2017) included data from 87 
historical controls and 3 current controls, of which 89 were men. 
*Statistically significant difference compared to IIM cases from present study. 
 
  Enzyme activities 
Results of fluorometric enzyme activity analysis are shown in Table 7. One IIM 
sample was omitted from PFK analysis because of a missing value. Although the activities 
of all measured enzymes were decreased in IIM cases compared too controls, the 
difference reached statistical significance for only two of the enzymes (3-HAD and CS). 
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 IIMs CONTROLS p-value 
Lactate dehydrogenase (LDH) 365.00 ± 84.74 484.60 ± 262.80 0.79 
3-hydroxyacyl-CoA dehydrogenase (3-
HAD) 
33.60 ± 10.83 66.82 ± 38.5 0.03 
Citrate synthase (CS) 13.06 ± 6.35 35.94 ± 15.69 <0.01 
Phosphofructokinase (PFK) 144.2 ± 84.58 199 ± 64.96 0.15 
 
Table 7. Fluorometrically measured enzyme activities in muscle homogenates of IIM 
cases and healthy controls.  
Enzyme activities are means ± SD and expressed as µmol/min/g protein. 
 
  Muscle fibre necrosis 
A total number of 2833 fibres were counted, with a mean of 567 fibres per IIM case 
(range 451 – 691). Of these, 30 fibres were found to be necrotic (1.1% of all fibres). The 
mean (± SD) percentage of necrotic fibres per participant was 1.1 ± 0.36%, with a range 
of 0.5 – 1.5%.  
 
2.5 Discussion 
The aim of this study was to investigate whether muscle fibre type distribution and 
size, as well as metabolic pathways, are affected in IIM. In addition, the magnitude of 
inflammatory necrosis in muscle from patients with these conditions was quantified.  
At 36%, the mean proportion of type I fibres in IIM muscle was lower than previously 
published data and reference values for healthy subjects, and 3 of the 5 IIM cases had 
mean type I proportions below 32.9%, the lower limit of normal (LLN) for healthy 
subjects.10 Two previous studies investigated fibre type proportion in the vastus lateralis 
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muscle of patients with IIMs. In an initial study by Dastmalchi et al. (2007) fibre type 
proportion was analysed in 9 patients with IIMs (5 PM, 4 DM) before and after a 12-week 
training program.70 They found a type I proportion of 32 ± 10% in IIM cases, versus 47 ± 
16% in controls. However, they studied only chronic, stable IIM cases, with a median 
disease duration of 22 months. All patients had undergone at least 1 year of 
immunosuppressive treatment, consisting of prednisolone with or without a steroid-
sparing agent. Therefore, whether the low type I proportion represented disease 
pathology or a treatment effect is not clear, as corticosteroid treatment is associated with 
a decrease in type I fibre proportion.71 Interestingly, the proportion of type I fibres 
increased to 42 ± 13% after training. In a further study by Loell et al. (2011) muscle 
biopsies from 38 patients with PM or DM were assessed , including 18 newly diagnosed, 
untreated patients, and 20 patients with chronic disease (more than 12 months disease 
duration post-diagnosis).72 The investigators found a decrease in type I fibre proportion 
in chronic disease (32 ± 16% in non-responders and 36 ± 10% in responders), but not in 
untreated patients (48 ± 14%) or healthy controls (47 ± 16%). They concluded that the 
low type I proportion was not a characteristic of PM or DM per se, but observed in treated 
patients with chronic disease. The findings from the present study therefore do not 
conform to those from the latter study, and warrant further exploration. In theory, a lower 
type I (and hence an increase in type II) fibre proportion could be a compensatory 
response, as peak force and power production by type II fibres is generally higher.73-75 
Unexpectedly, mean CSA of all three fibre types (I, IIA, IIX) were found to be 
increased in IIM cases, compared to published data and reference values. Although the 
difference reached statistical significance only for type IIX fibres, this is almost certainly 
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due to the small number of IIM cases included. Although variations in muscle fibre size 
and muscle fibre atrophy (and not hypertrophy) have been reported since the 1960’s,76,77 
data using standardized methods for quantification is sparse. Loell et al. (2011) assessed 
CSA of type I and type II fibres in 18 untreated and 20 treated PM and DM cases, and 
compared it to healthy controls.72 No differences were found between any of the groups. 
It therefore appears that results of muscle fibre size analysis should be interpreted with 
caution, as findings are heterogeneous across studies, including data from healthy 
controls. In their meta-analysis of data from 19 studies, including 423 healthy subjects, 
Gouzi et al. (2013) found significant heterogeneity between included studies, with an I2 
index of 36%.10 Mean fibre CSA ranged from 2 858 ± 648 µm2 to 5 892 ± 1095 µm2 
between studies. Based on these findings, it is prudent to avoid over-interpretation of CSA 
values, in both health and disease. 
Enzyme analysis revealed significantly decreased activities of both 3-HAD and CS 
in IIM muscle samples, indicating impaired fat and carbohydrate oxidative capacity. 
Although LDH and PFK activities were also decreased, the differences did not reach 
statistical significance, and the effect sizes were also smaller. Whether lactate 
metabolism and glycolysis are also affected therefore remains unclear. A previous study 
investigating the effect of a 12-week endurance training program on exercise capacity in 
patients with stable IIMs was able to show both clinical improvement and increased 
muscle mitochondrial enzyme activities (CS and 3-HAD).66 However, enzyme activity was 
not measured in healthy controls for comparison at baseline or after training, and it is 
therefore not clear whether the increase in enzyme activities happened against a 
background of impaired activity at baseline. It is well established that endurance training 
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leads to increased activity of muscle mitochondrial enzyme activities, both in healthy 
humans and in rats.78-82 It is therefore reasonable to expect a similar response to 
endurance training in diseased muscle, although the magnitude may differ. Whether the 
metabolic abnormalities illustrated in the present study contribute to the development of 
weakness in IIMs or are simply the result of the disease process, therefore remains to be 
investigated. Furthermore, since enzyme activity appears to correlate with physical 
activity, the decreased activities shown in the present study may merely be a marker of 
physical inactivity due to muscle weakness. This hypothesis is supported by the fact that 
the median MRS of IIM cases was 3 (moderate disability; requiring some help, but able 
to walk without assistance), indicating significant limitation on activity. 
In keeping with a previous study,39 quantitative analysis showed that ~1% of fibres 
in muscle biopsies from IIM cases are necrotic. This relatively low number suggests that 
widespread necrosis is unlikely to be the main contributor to weakness observed in this 
condition. It could be argued that muscle fibre necrosis is an ongoing process leading to 
cumulative loss of muscle fibres, while muscle histology provides only a snapshot of the 
process at a particular time. Although this may potentially explain weakness in 
longstanding or treatment-resistant cases, it would not explain recent onset cases with 
clear weakness despite minimal loss of fibres on histology. 
 
Study limitations 
The main limitation of the study is the relatively small number of muscle biopsies 
from IIM cases that were analysed, which is related to the rarity of these disorders. 
Whether the findings are representative of this group of disorders is therefore uncertain. 
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However, many of the findings were in keeping with previously published data. Of 
particular interest are the unexpected findings of increased fibre size in IIM. Again, 
because of the small number of biopsies, reliable comparison of muscle fibre size 
between patients with IIMs and healthy controls could not be made, because of the small 
number of IIM cases included in the study. Another limitation is incomplete matching for 
age and gender. Because we utilized opportunistic recruitment and sampling, it was not 
possible to fully match cases and controls. However, this could only potentially have an 
influence on the enzyme analysis, as muscle fibre type and size was compared to the 
published literature and not healthy controls.  
 
2.6 Conclusion 
The main findings of the study are that, in addition to the well-known histological 
features, morphometric and metabolic alterations are present in muscle of patients with 
IIMs.  Although muscle fibre necrosis is a common and characteristic feature of IIMs, its 
contribution to symptomatology, notably weakness, remains unproven and can probably 
be regarded as negligible based on the finding of this and other studies. It is a distinct 
possibility that these morphometric and metabolic changes are merely consequences of 




3 IN VITRO CONTRACTILE FORCE MEASUREMENT OF SINGLE MUSCLE 




3.1 Introduction and background 
Force generated by a muscle is directly related to the number of contracting muscle 
fibres and the contractile force generated by each of the individual fibres. Therefore, 
weakness of a muscle may result from either quantitative (decrease in the number or size 
of functioning muscle fibres in the muscle) or qualitative (impaired function of contractile 
apparatus of individual muscle fibres) factors.  
Multiple processes may lead to a decrease in fibre number or size, such as myofibre 
necrosis, ischemia and denervation. However, the primary outcome from these processes 
is a decrease in the total number of actin-myosin cross-bridges that participate in force 
generation. In addition, contractile apparatus function (which is dependent on the 
interaction between actin and myosin filaments) may be affected by numerous factors, 
including abnormalities in structural proteins, impaired energy supply, alterations in 
calcium homeostasis, or combinations thereof.  
The assessment of muscle strength can be performed on multiple levels, including: 
• System level: Timed functional tests, e.g. rising from a chair, 30 metre walk test. 
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• Organ/muscle level: Manual muscle testing, dynamometry. 
• Cellular/muscle fibre level: in vitro permeabilised single muscle fibre contractility 
testing. 
• Molecular level: in vitro motility assay to measure the translational velocity of actin 
filaments on myosin.  
 
In vitro single muscle fibre contractility studies make it possible to directly assess 
the function of the cellular contractile apparatus in both healthy and diseased muscle, and 
are ideally suited to study muscle function at a cellular level. In order to elucidate both the 
advantages and the shortcomings of single fibre contractility studies, a brief stepwise 
explanation of the technique is warranted:  
i. Bundles of muscle fibres are chemically permeabilised. This step is necessary to allow 
the different solutions to freely enter the fibre without restriction from the sarcolemma. 
For example, in vivo, intracellular Ca2+ is made available in response to an action 
potential that is sensed by the dyhidropyridine receptor (DHPR) on the T-tubule, leading 
to fast  Ca2+ release from the sarcoplasmic reticulum via ryanodine receptor opening. 
As the latter process cannot be accomplished in resected muscle fibres, the membrane 
must be permeabilised to allow Ca2+ influx based purely on a concentration gradient. 
ii. A single muscle fibre is dissected from the bundle and attached to aluminium clips at 
both ends (Figure 9). 
iii. The permeabilised fibre is suspended between a lever arm connected to a motor on 
the one side and a force transducer on the other and bathed in a solution that allows 
the fibre to be stretched without  opposing forces from the contractile proteins.  
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iv. The fibre is sequentially submerged in different solutions (e.g. activating solution) and 
the contractile apparatus exposed to the constituents of the solution, leading to either 
contraction or relaxation. 
v. The contractile force generated by the fibre is recorded by the force transducer. 
 
The technique has a number of advantages: 
i. The factors that complicate the assessment of individual muscle function in vivo (e.g. 
muscle fibre orientation, the presence of endomysial connective tissue due to chronic 
disease, variation in motor unit recruitment, or muscle co-activation) are circumvented 
in single fibre studies. 
ii. On a cellular level, the technique enables the functional assessment of the contractile 
apparatus in isolation. This is accomplished by directly providing the contractile 
apparatus with the constituents required for contraction (e.g. calcium, ATP), thereby 
circumventing processes such as neuromuscular transmission, ATP production and 
Ca2+ influx. When normalised to muscle fibre diameter, the contractile force produced 
by a fibre therefore provides a direct assessment of the function of the contractile 
apparatus. 
These factors make single muscle fibre contractility studies a valuable tool to 
investigate the mechanisms of muscle dysfunction in muscle disorders. Together with 




3.2 Synopsis of current literature 
Single fibre contractility studies have been utilised in many studies of both healthy 
individuals as well as people with different disorders that may affect muscle strength, 
including systemic disorders and disorders limited to the neuromuscular system. In 
healthy individuals, these include exploration of the effects of sex,75 age,75 exercise,83-85 
and even zero gravity environments during prolonged space flight.86 Neurological 
disorders investigated by means of single fibre contractility studies include myopathic 
disorders,18-20,87 neurogenic disorders,88,89 and long-term paralysis due to chronic spinal 
cord injury.90 In the case of IIMs, the possibility of impaired contractility has not been 
adequately explored. 
 
 Assessment of single muscle fibre function in IIM 
To date, only a single study evaluating in vitro single muscle fibre function in 
untreated DM has been performed.46 Five patients were included, and compared with 
healthy controls. No differences in SF of type I fibres were found between the two groups, 
although SF of type IIa fibres was greater in patients with DM than in controls. 
Furthermore, type I fibres of patients with DM had a higher unloaded shortening velocity 
(V0) than those of healthy volunteers. Given these findings, it was proposed that the force 
generating capacity and shortening velocity of the remaining (surviving) muscle fibres are 
preserved in DM.  
However, this study had some shortcomings. Firstly, and most importantly, the 
biopsied muscles in patients with DM were either of normal strength or only mildly weak 
(median MRC grade 4+/5, range 4-5). Impaired contractility as a sole or contributing 
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cause of weakness cannot be reliably excluded in the absence of significant clinical 
weakness in the biopsied muscles, as the muscle tissue obtained from such a muscle 
may not be representative of the processes leading to weakness. Secondly, not all 
biopsies were taken from the same muscle: all control biopsies were from the vastus 
lateralis muscle, while DM biopsies were from the biceps or deltoid muscles. Although 
studies comparing contractile force between different muscles, have not been performed, 
it cannot be assumed to be similar. Ideally, therefore, muscle biopsies should come from 
the same muscle in both groups. Muscle fibre contractility in IIMs therefore remains 
largely unexplored. The findings in this study have not been duplicated, and, as explained 
in chapter one and in section 2.2 below, data from animal studies suggest that contractility 
is indeed impaired in response to the presence of inflammatory mediators. 
 
 Mechanism of muscle fibre dysfunction in animal models of IIMs 
As referred to in chapter one, exogenous TNF-α has been shown to decrease 
contractile force in diaphragmatic and limb muscles in animal models, both in vivo and in 
vitro.42,44,43 A single study evaluated contractility in chemically permeabilised murine 
diaphragmatic single muscle fibres after intraperitoneal injection of TNF-α.91 TNF-α 
decreased the force generated by myofibrillar proteins, acting via the TNF type I receptor 
subtype. The underlying mechanism appears to be mediated by TNF-stimulated oxidants, 
either reactive oxygen species (ROS), nitric oxide (NO), or both. No comparable studies 
on human skeletal muscle have been performed. 
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3.3 Purpose of the study 
  Aims and objectives 
The aim of the study was to determine whether the function of the contractile 
apparatus of muscle fibres from patients with IIMs is affected by the disease process. In 
order to investigate this question, in vitro single muscle fibre contractility studies were 
performed to assess the maximum contractile force of the fibres from patients with IIMs 
and compare the results to those from healthy controls. The specific objectives of the 
study were:  
i. To measure and compare the contractile force of single muscle fibres from patients 
with treatment-naïve IIMs to that of fibres from healthy volunteers. 
ii. To correlate the contractile properties from the single fibres with clinical features 
(weakness) in patients with IIMs. 
 
  Hypothesis 
The hypothesis is that weakness in IIMs is related not only to a decrease in the 
number of muscle fibres (i.e. a structural abnormality due to inflammatory necrosis), but 
also to an impairment in the contractile function of individual muscle fibres (i.e. a functional 
abnormality). Therefore, it was hypothesised that single fibre contractility studies would 
reveal a decrease in both maximum force (P0) and SF of muscle fibres from patients with 
IIMs. It was furthermore hypothesised that the reduced force production would correlate 




  Sources of muscle biopsy specimens 
Muscle biopsy specimens were obtained from cases and controls as described in 
chapter two.  
 
  Specimen acquisition, storage and preparation 
The acquisition and storage of muscle samples were described in chapter two. Prior 
to analysis, each of the stored samples was thawed briefly in PBS at 37°C for 1 minute 
and divided into small bundles, each consisting of 20-40 muscle fibres. These bundles 
were then submerged into skinning solution containing 50 % glycerol (pH 7.00), and 
stored at 4°C for 24 hours. After 24 hours, the skinning solution was replaced with fresh 
skinning solution and subsequently stored at -20°C until analysis. 
 
  Equipment 
Single fibre contractility assays were performed on an Aurora Scientific 1400A 
permeabilised fibre test system (Aurora Scientific, Ontario, Canada). The system 
essentially consists of a force transducer and a motor to which each end of the fibre was 
attached, and a bath plate containing baths for different solutions into which the fibre is 
submerged (Figure 8). Details about the different solutions utilised in the study is provided 















In order to attach each end of the fibre to the force transducer and motor, 
respectively, the fibre needs to be attached to two aluminium T-clips (Figure 9). Due to 
the exorbitant cost of commercially available T-clip templates, T-clips were made from 
aluminium kitchen foil based on previously described techniques, with some 








Figure 8. Components of the permeabilised fibre test system. 
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Figure 9. A muscle fibre attached to aluminium clips is shown next to a human hair for 
size perspective. 
 
  Measurement of maximum force 
Contractile properties of skinned single fibres were analysed based on the methods 
described by Kohn et al.94 All measurements and pH adjustments were performed at 
12˚C. The volumes and concentrations of all solutions for the single fibre contractile 
properties were calculated using the computer program described by Dweck et al.,95 
based on that first published by Fabiato and Fabiato.96  
On the day of the experiment, single fibres were dissected under a 
stereomicroscope and attached to aluminium T-clips (for an illustrational video on the 
dissection and attachment of muscle fibres, see: http://www.myolab.co.za/about-
me/technology/technology-contraction/). The single fibre was then attached to the force 
transducer and motor and submerged in a relaxing solution containing 5 mM EDTA, 20 
mM Imidazole pH 7.00, 5.08 mM ATP, with a total ionic strength of 180. The –log 
concentration of free ions amounted to: pMg 3.00, pCa 9.00 and pATP 2.40. After 
 62 
mounting, the fibre was allowed to equilibrate in the relaxing solution for approximately 5 
minutes. During this time, the fibre was stretched to obtain a sarcomere length of between 
2.40 and 2.70 µm, the optimal sarcomere length to produce maximum contractile force. 
Digital images were recorded at 40x, 100x and 200x magnification for the determination 
of fibre length, diameter and sarcomere spacing, respectively, using a camera attached 
to the microscope (Figure 10). The fibre dimensions were determined using pre-calibrated 
software (AxioVision, Zeiss Inc., Germany). It was assumed that fibres have a circular 
shape, and CSA was determined from the diameter of the fibre using the equation π 
[(0.8×fibre diameter)/2]2, where 0.8 is to correct for an estimated 20% fibre swelling.97 All 
subsequent operations were controlled by the software program of the permeabilised 
single fibre system.  
Once equilibrated, the fibre was transferred to a bath containing a pre-activation 
solution (concentrations listed as above for relaxing solution, but with 0.5 mM EDTA, 14.5 
mM creatine phosphate and 200 U/ml creatine kinase) for 30 seconds, where after it was 
transferred to an activating solution. The latter contained 5 mM EDTA, 20 mM imidazole 
pH 7.00, 5.08 mM ATP, 14.5 mM creatine phosphate and 200 U/ml creatine kinase. The 
–log concentration of free ions amounted to: pMg 3.00, pCa 4.50 and pATP 2.40. This 
concentration has been shown to elicit maximum contraction in human muscle 
fibres85,73,98. Progress of contraction was followed on the recording program, and once a 
steady state of maximum force was reached, the fibre was transferred back to the relaxing 
solution. Force was measured in millinewtons (mN). Next, the fibre was randomly 
assigned to either force clamp studies for determination of Vmax (~70 % of fibres) or 




Figure 10. High-magnification photograph of a muscle fibre showing the striations, 
consisting of A-bands (dark) and I-bands (light). 
 
  Determination of myosin heavy chain composition 
After force measurements were performed, each fibre was placed in a plastic 
microfuge tube containing 90 µl reducing sample buffer, and stored at -20˚C. The MyHC 
composition of each fibre was determined by means of sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) according to Kohn et al.99 On the day of 
the experiment, 10 µl β-mercaptoethanol was added to each sample and the samples 
were heated at 95˚C for 5 minutes. The acrylamide concentrations were 4% (v/v) in the 
stacking gel and 7% in the separating gel. MyHC isoforms were identified using a 
homogenate that contained all three human MyHC isoforms (see Figure 11 for example). 
Approximately 25 µl of each single fibre preparation was loaded into each well, and 10 µl 
for the myosin homogenate. 
 
 Statistical analysis 
SF was calculated as P0 normalized to CSA and expressed as kN/m2 (kilonewtons 
per square metre).  
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The D’Agostino & Pearson normality test was used to test data for normality of 
distribution. Because none of the data sets displayed a normal distribution, the non-
parametric Mann-Whitney test was used to compare differences in means. Strength of 
association between variables was tested by means of the Spearman’s Rank Correlation 
Coefficient. Statistical analysis was performed using GraphPad Prism version 7 
(GraphPad Software, La Jolla, California). For all parameters, mean ± SD was calculated, 
unless stated otherwise. Statistical significance was set at P<0.05. Power calculations 
were performed using G*Power Version 3.1.9.2 (Erdfelder, Faul & Buchner, 1996). 
 
 
Figure 11. Electrophoretic separation of MyHC isoforms.  
A muscle homogenate that contained all three MyHC isoforms (control) assisted in the 
identification of the single fibre isoforms. 
MyHC: myosin heavy chain 
 
3.5 Results 
Participants included in this study consisted of six healthy controls (two male, four 
female) and five patients with IIMs (all female). The IIM group consisted of one patient 
with PM, two with DM, and two with NAM. The median MRC score for the IIM group was 
4 (range 4- to 5). Overall, 178 single fibres were studied from patients with IIMs; this 
included 55 type I fibres, 98 type IIa fibres, six type IIx fibres, and 19 hybrid fibres (13 
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I/IIa, two I/IIx, four IIa/IIx). A total of 174 fibres, consisting of 96 type I fibres, 65 type IIa 
fibres, one type IIx fibre, and 12 hybrid fibres (10 I/IIa, one I/IIa/IIx, one IIa/IIx), were 
studied from the healthy control group. 
 
 Analysis by group (IIM vs healthy controls) 
The contractile properties of IIM cases and controls were analysed for all fibre types 
combined (types I, IIa, IIx and hybrid), as well as for type I and IIa fibres separately. Type 
IIx and hybrid fibres were not analysed separately due to the small numbers of these 
fibres in the biopsies.   
When all fibre types were combined, mean CSA of fibres from the IIM group was 
approximately 6% smaller than those from the control group (4 366 ± 2 337 µm2 vs. 4 628 
± 1 749 µm2; p=0.02). This difference was due to a smaller fibre size of type I fibres: when 
analysed separately, mean type I fibre CSA in IIM biopsies was 26% smaller than controls 
(3 342 ± 1 787 µm2 vs 4 486 ± 1 703 µm2; p<0.001), while type IIa fibre CSA was identical 
(4 796 ± 2 462 µm2 vs 4 806 ± 1 815 µm2; p=0.48), as illustrated in Figure 12. These 
findings are in contrast to those of comparative morphometric analysis described in 
chapter 2, which showed increased CSA for both fibre types when compared to published 
reference values and case series. The reason for this discrepancy in Type I fibre size 
between morphometric analysis and single fibre measurement is not clear, as selection 
of fibres for single fibre analysis is completely random. 
Both maximum and SF measurements revealed statistically significant differences 
between cases and controls, not only for all fibres combined but also divided into fibre 
type. For all fibres combined, P0 was 27 % lower in the IIM cases (0.33 ± 0.18 mN vs. 
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0.45 ± 0.17 mN; p<0.001, power = 0.99), while SF was 23 % lower (81 ± 38 kN/m2 vs. 
105 ± 45 kN/m2; p<0.0001, power = 0.99). For type I fibres, P0 was 48 % lower in the IIM 
cases (0.21 ± 0.09 mN vs. 0.40 ± 0.15 mN; p<0.0001, power = 1.00) and SF 24 % lower 
(73 ± 36 kN/m2 vs. 96 ± 36 kN/m2; p<0.0001, power = 0.96). For type IIa fibres, P0 and 
SF were both 29% lower in IIM cases: P0 was 0.37 ± 0.18 mN and 0.52 ± 0.20 mN in IIM 
and control fibres, respectively (p<0.0001, power = 0.99), while SF was 84 ± 36 kN/m2 
and 118 ± 48 kN/m2 (p<0.0001, power = 0.99). These results are presented in Figure 13 




Figure 12. CSA of type I and IIa fibres (mean + SD).  




Figure 13. P0 of type I and IIa fibres (mean + SD).  
P0: Maximum force. 
 
 
Figure 14. SF of type I and IIa fibres (mean + SD).  
SF: Specific force. 
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  Analysis by diagnostic subgroup 
In order to investigate whether the findings seen in the IIM group as a whole were 
present in all subgroups (PM, DM and NAM) and not merely the result of a large effect 
size in one or two subgroups, fibres were also analysed in these different subgroups and 
compared to the healthy controls (whole group).  
In the DM subgroup, type I, but not type IIa fibres, were significantly smaller in size. 
P0 was significantly decreased for both fibre types, but SF was significantly decreased 
only for type IIa fibres. Interestingly, the type IIa fibres in the NAM subgroup were larger 
in size than in controls, while no significant difference was detected for type I fibres. P0 
was decreased for type I fibres, but identical for type IIa fibres (despite the increased 
CSA), while SF was significantly decreased for both fibre types. In the PM group, fibre 
size was significantly smaller for both fibre types, as was P0. SF was significantly 
decreased for type I fibres, while there was a non-significant trend towards decreased SF 
for type IIa fibres. The results are shown in Table 8 and Table 8, while Table 10 provides 




 IIMs CONTROLS 
 DM p-value* NAM p-value* PM p-value*  
Number 14  15  26  96 
CSA (µm2) 
3 108  
± 1 702 
<0.01 4 633  
± 2 325  
0.88 2 724  
± 969 
<0.0001 4 486  




<0.001 0.21  
± 0.08 
<0.0001 0.19  
± 0.07 





0.37 55  
± 30 
<0.0001 76  
± 34 
<0.01 96  
± 36 
 
Table 8. Contractile properties of type I fibres analysed by diagnosis.  
Values are mean ± SD. CSA: cross-sectional area; P0: maximum force; SF: specific force; SD: 
standard deviation. 
*p-values are calculated for each diagnostic subgroup compared to control group as a whole. 
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 IIMs CONTROLS 
 DM p-value* NAM p-value* PM p-value*  
Number 59  21  18  65 
CSA (µm2) 
4 774  
± 2 410 
0.63 6 407  
± 2 434 
<0.01 2 990  
± 1 058 
<0.001 4 806  




<0.001 0.52  
± 0.15 
0.70 0.29  
± 0.09 





<0.001 90  
± 36 
<0.01 100  
± 51 
0.27 118  
± 48 
 
Table 8. Contractile properties of type IIa fibres analysed by diagnosis. 
Values are mean ± SD. CSA: cross-sectional area; P0: maximum force; SF: specific force; SD: 
standard deviation. 
*p-values are calculated for each diagnostic subgroup separately compared to control group as 
a whole. 
 
Table 10. Summary of contractile properties of type I and IIa fibres analysed by 
diagnosis. 
↓: Significantly lower compared to control group; ↑: Significantly higher compared to control 
group; ↔: No difference compared to control group. 
 
 
 DM NAM PM 
 Type I Type IIa Type I Type IIa Type I Type IIa 
CSA (µm2) ↓ ↔ ↔ ↑ ↓ ↓ 
P0 (mN) ↓ ↓ ↓ ↔ ↓ ↓ 
SF (kN/m2) ↔ ↓ ↓ ↓ ↓ ↔ 
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 Contractile properties of individual IIM participants 
To investigate whether contractility data correlated with clinical weakness, mean P0 
and SF was calculated separately for each IIM participant (combined for all muscle fibre 
types), and plotted against MRC grading of muscle strength for knee extension, the action 
that vastus lateralis contributes to. Although strength was not formally tested in healthy 
controls, this was regarded as normal as, by definition, they had no complaints of 
weakness and no functional impairment. The Spearman’s Rank Correlation Coefficient 
(r) was 0.674 (p=0.04), indicating moderately good correlation. The results are shown in 
Figure 15.  
 
 
Figure 15. Mean specific force of all fibre types combined per participant (coloured 
columns, left Y-axis) and MRC strength grade of biopsied muscle (black-and-white dotted 
columns, right Y-axis).  
HCM: Healthy control male; HCF: Healthy control female; DM: Dermatomyositis; NAM: 




In order to investigate the mechanism behind weakness in IIMs, single fibre 
contractility studies were performed on muscle fibres from patients with IIMs, and 
compared  to fibres from healthy controls. The findings of this study suggest that 
contractile force is impaired in IIMs. The impairment in contractile force can partially be 
explained by the fact that muscle fibre diameter is decreased in IIMs, leading to a 
decrease in maximum force production per fibre. However, there also appears to be an 
impairment in contractile force independent of a decrease in muscle fibre diameter, as 
evidenced by decreased contractile force after correcting for CSA (specific force, SF). 
The implication of this finding is that a functional impairment of muscle fibre contraction 
is present in IIMs, unrelated to a decrease in muscle fibre diameter. 
The findings of this study provide a basis for further investigation into the possible 
mechanisms underlying weakness in IIMs. A number of different mechanisms have been 
proposed, but some of these cannot fully explain the findings. One such mechanism 
involves high mobility group box protein 1 (HMGB1), which may act via toll like receptor 
4 (TLR4) to accelerate muscle fatigue in fibres by reducing the SR Ca2+ release.100 This 
finding suggests that weakness and fatigue may result from impaired Ca2+ release from 
the SR. However, in the current study, the observed impaired contractility could not be 
explained by this phenomenon, as the Ca2+ required for contraction during single fibre 
studies is exogenously provided to the fibre through the activating solution and not 
released from the SR. Therefore, although impaired Ca2+ release leading to fatigue may 
partially explain fatigue in IIMs, it is unlikely to be an important mechanism in the 
development of impaired contractility. Similarly, these results do not support a prominent 
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role for abnormalities in energy metabolism, e.g. AMPD1 deficiency,37 as contractility is 
impaired despite a sufficient supply of ATP by the activating solution. It also lends further 
support to the notion that the impaired enzyme activity described in Chapter 2 is a 
consequence of the disease process (e.g. related to inactivity) and is unlikely to contribute 
significantly to the development of muscle weakness. Therefore, although these 
mechanisms may contribute to weakness and fatigue, they do not explain the findings 
from this study of contractile dysfunction in muscle fibres from patients with IIMs. 
In view of these findings, a more plausible explanation involves an interaction 
between one or more components of the inflammatory response and the contractile 
apparatus or its supporting structures. One such component is TNF-α, which has been 
shown to decrease contractile force of skeletal muscles in animal models.42,44,43,91 In a 
study published in 1994, Wilcox and colleagues were able to show that infusion of TNF- 
α decreased diaphragm contractility in anaesthetised dogs by ~20 % within 3 hours and 
by ~50 % at 6 hours post-infusion.44 Diaphragm contractility in this study was assessed 
by measuring force and shortening of the diaphragm in vivo during supramaximal phrenic 
nerve stimulation. It was therefore not possible to reliably localise the site of action of 
TNF-α, which could have been due to impaired transmission at the distal nerve, 
neuromuscular junction or along the sarcolemma, or due to impaired contractile function 
of the muscle fibres. In a subsequent study published in 1996, the same group performed 
in vitro assessment of excised hamster diaphragm contractility in response to incubation 
with high-dose TNF-α.43 They were able to show an impairment in contractility in response 
to direct electrical muscle stimulation, thereby localising the site of action to muscle. In 
addition, they could illustrate partial blocking of this effect by indomethacin, an inhibitor of 
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cyclooxygenase, the rate-limiting enzyme in prostaglandin synthesis. This would suggest 
that the effect of TNF-α is mediated, at least in part, by cyclooxygenase products. In 2004, 
it was shown that TNF-α effects on muscle function were evident at the myofibrillar level 
in mice.91 The euthanized animals received an intraperitoneal injection of TNF-α (or buffer 
for controls), and the diaphragms were excised 1, 2, 4, 24 or 48 hours after injection. 
Upon direct electrical muscle stimulation, maximal force was depressed by 25 % after 1 
h, a response that persisted for at least 48 hours. Similarly, TNF-α decreased maximum 
SF of calcium-activated permeabilised diaphragm single muscle fibres, suggesting 
impaired contractility due to myofibrillar dysfunction. This effect appeared to have been 
mediated by oxidant activity, as intracellular oxidant activity was increased 1 h after TNF-
α administration, and pre-treatment with Trolox (a hydrophilic antioxidant), diminished 
intracellular oxidant activity and abolished the decrement in SF of muscle fibres from TNF-
α-treated animals. Li and colleagues (2000) came to a similar conclusion, showing 
decreased force production in mouse diaphragm fibre bundles in response to exogenous 
TNF-α.41 The decreased force production was associated with greater intracellular 
oxidant levels and inhibited by incubation with the antioxidant N-acetylcysteine. 
From a therapeutic perspective, if TNF-α is indeed an important role player in the 
development of contractile dysfunction, agents targeting this cytokine should theoretically 
result in clinical improvement. Monoclonal antibodies against TNF-α have recently 
become available, and some clinical data on one of these agents, infliximab, is available. 
This data is unfortunately limited to retrospective case series and a single, small 
randomized-controlled trial.101-103 Although most cases showed a favourable response, 
some continued to worsen or discontinued treatment due to adverse events. However, 
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patients receiving infliximab in these series were all refractory to standard treatment, 
implying difficult to treat forms of the disease. More importantly, because disease duration 
in these patients was many years, it is highly likely that irreversible muscle damage had 
already occurred by the time infliximab was administered. Therefore, the apparent 
inefficacy of infliximab in some of the patients does not necessarily indicate an incorrect 
treatment target, but rather an irreversible stage of the disease. To reliably assess the 
efficacy of TNF-α inhibition, randomized controlled trials including treatment-naïve 
patients are required. 
A number of different explanations for the impaired contractility should also be 
considered. Firstly, it is possible that the inflammatory process may have a deleterious 
effect on actin-myosin interaction, either by decreasing the amount of strongly bound 
interactions during maximal contraction, or a lower force generated by each individual 
interaction, or both. In a study evaluating the effect of age and immobilisation on single 
fibre contractility, D’Antona et al. (2003) were able to show a linear correlation between 
myosin concentration and loss of specific force.74 This finding suggested that a lower 
number of interactions was responsible for the observed decrease in specific force of 
single fibres with aging and after immobilisation. In a different study of skinned fibres from 
elderly rats, Lowe et al. (2001), showed a reduced fraction of myosin heads in the strong-
binding structural state with maximal activation.104 Alterations in actin-myosin interactions 
and how they may be affected by the inflammatory response in IIMs have not been 
investigated, and warrant further consideration. 
Another factor that may influence muscle fibre contractility is post-translational 
modification of myosin, of which the best studied example is phosphorylation. In 
 76 
sarcomeric myosins, the Ca2+/calmodulin-dependent skeletal muscle myosin light chain 
kinase (skMLCK) is responsible for phosphorylation, and phosphorylation sites are 
located on the regulatory myosin light chains (MyLC).105 Phosphorylation of MyLC 
modulates Ca2+ / troponin-dependent force generation by promoting movement of the 
myosin heads out of the off-state.106 However, impaired phosphorylation is unlikely to 
contribute to muscle fibre force generation for two reasons. Firstly, MyLC phosphorylation 
increases Ca2+ sensitivity and force at submaximal Ca2+ levels, and cannot explain the 
decreased force generation at maximal activation.107,108 Secondly, and probably most 
importantly, although phosphorylation of MyLC has not been investigated in IIMs, other 
inflammatory disorders like inflammatory bowel disease (IBD) are associated with 
increased and not decreased MyLC phosphorylation.109 Interestingly, this process 
appears to be mediated by inflammatory cytokines, in particular, TNF-α and IL-1β.110 
In addition to the direct effects of the disease process on force production, the 
indirect effects, i.e. the role of muscle disuse/inactivity should also be considered. A 
number of studies investigated the effects of both long term and short term immobilization 
on contractile properties of skeletal muscle fibres, and a decrease in force was shown in 
some,74,111,112 but not all of these studies.90 However, it has to be noted that the extent of 
immobilisation was substantial in these studies (complete immobilisation, bed rest or 
chronic spinal cord injury), while all participants in the current study were still mobile, but 
had decreased activity due to weakness and fatigue. 
Finally, the influence of the disease process on the amount of muscle fibre swelling 
should be considered. Although swelling was taken into account and corrected for, it is 
possible that the amount of swelling of IIM fibres exceeds that of control fibres. 
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Underestimation of the amount of swelling will lead to underestimation of the specific 
force. However, the CSA of IIM fibres in this study was decreased compared to controls. 
Although this does not necessarily exclude the presence of some intracellular oedema, it 
makes it highly unlikely. Furthermore, swelling of individual muscle fibres is not a reported 
feature on histological and ultrastructural assessment of inflammatory myopathy. In view 
of above, fibre swelling is unlikely to influence the results of this study.  
During single fibre testing, muscle fibres from IIM cases were perceived to be 
substantially more fragile than fibres from controls, resulting in difficulty mounting the 
fibres in the aluminium clips without breaking them, and increased tearing of fibres during 
stretching to the desired sarcomere length. An attempt to quantify this was not made, as 
this was only observed during the course of the study. Although not likely, it is conceivable 
that the impaired force production may serve to protect the fragile fibre from irreversible 
damage. Assessment of the structural integrity of muscle fibres in IIMs should be 
considered in future research. 
 
Study limitations 
This study has a number of potential limitations. Firstly, it could be argued that the 
different disease entities included in the IIM group all have different pathological 
mechanisms. While this may be true, they also share a number of characteristics, some 
of which may be relevant to the context of the current study and provide sufficient 
justification to “lump” these entities together for the purpose of this investigation, as 
discussed in chapter one. Although the inclusion of sufficient numbers of patients with 
each of the separate disease entities would be ideal, such investigations are limited by 
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the rarity of the disorders and the time-consuming nature of the experiments. 
Furthermore, subgroup analysis of fibres from the different diagnostic subgroups, despite 
being limited in number, still revealed significantly impaired SF for one or both fibre types 
in each group (Table 8 and Table 8). A second limitation is incomplete matching for sex 
and age in the control group. Two of the six controls were male, while all five IIM cases 
were female, and the mean age in the IIM group was substantially higher. However, this 
is unlikely to have influenced the main results, as it has been shown that greater strength 
in men is primarily related to larger diameter of muscle fibres,113 and both SF and 
normalised peak power are similar in men and women, as well as young and old.75 One 
study did show decreased SF in elderly compared to young subjects (22% lower for type 
I and 16% lower for type IIa fibres), but the difference in median age between the elderly 
and young group was substantial (72.7 vs. 30.2 years).114 In contrast, the median ages in 
the current study were 48 and 30 years for the IIM cases and controls, respectively, and 
the oldest participant in the IIM group was 60 years of age. 
The reason for the finding of increased CSA of type IIa fibres from the NAM group 
is unclear. This finding has not been described before, and needs to be duplicated in a 
larger sample of patients with NAM. However, as discussed in chapter 2, there appears 
to be marked variation in CSA between individuals and between different studies, and 
caution is advised when interpreting fibre size data. 
 
3.7 Conclusion 
The results of this study suggest that maximal force generation of muscle fibres 
from patients with IIM are adversely affected by the disease process. The impaired 
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contractility correlates with weakness of the biopsied muscle, and could, at least partially, 
explain the presence of weakness in these disorders. Further studies are required to 
elucidate the pathological mechanism responsible for the development of the impaired 
contractility. In particular, the role of the pro-inflammatory cytokine TNF-α warrants further 





4 FORCE-VELOCITY AND FORCE-POWER RELATIONSHIP OF SINGLE 




4.1 Introduction and background 
In addition to measurement of force, contractile properties of muscle fibres can be 
further characterised by measurement of shortening velocity (V) at different loads/forces 
(including the unloaded state, i.e. P = 0 mN). When a muscle fibre contracts, the amount 
of force produced is dependent on the degree to which its ends are restrained. When an 
isometric contraction takes place (i.e. no shortening), force is maximal (P0), while velocity 
will be zero, as the fibre length does not change, even though the myosin and actin still 
undergo vigorous cross-bridge cycling. If the ends are completely free, no force is 
produced and the fibre shortens at maximum velocity, which is termed unloaded 
shortening velocity (Vo). It is not possible to determine maximum shortening velocity if the 
ends of the fibre are attached, but the Hill equation is used to determine maximum velocity 
(Vmax) when the fibres are attached. Between these two extremes, the relation between 
force and shortening velocity can be described as part of a rectangular hyperbola (Figure 
16). This relation, first characterised by A.V. Hill in 1938, can be described by the equation 
(P + a)(V + b) = (P0 + a)b, where P is the force during shortening at velocity V, P0 is the 
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force during an isometric contraction, and a and b are constants, and is known as Hill’s 
equation.115 The curvature of the hyperbola is given by the value of a/P0. Many 
investigators prefer determination of Vmax, as it represents a closer simulation of 
physiological conditions, and enables the construction of velocity-force and power-force 
curves. It is important to note that, while the value of P0 depends on the number of cross-
bridges that are attached (and therefore the degree of filament overlap), the value of Vmax 
reflects the rate of cross-bridge turnover and is independent of the number of cross-
bridges in operation.116-118,4 
 
 
Figure 16. Force-velocity curve of a type I muscle fibre.  
Force (x-axis) is expressed as percentage of P0. The hyperbola meets the X-axis at P0 and the 
Y-axis at Vmax. The curvature of the hyperbola is given by the value of a/P0. P0: maximum force; 
Vmax: maximum shortening velocity. 
 
Measurement of Vmax is more complicated than measurement of force. In order to 
determine Vmax, conditions of zero load need to be recreated or simulated. Two main 
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techniques have been described, the slack test and the force clamp test. The slack test 
was first described by Edman (1979) and is performed by rapidly releasing the tension to 
zero during a contraction and measuring the time to the start of tension redevelopment.118 
This is repeated at different magnitudes of release, and the slope of the relation between 
size of the release and measured time represents the steady state shortening velocity at 
zero load (V0), which is different from maximum shortening velocity at zero load (Vmax). 
Vmax is derived from the force-velocity curve by extrapolation of data obtained with force 
clamp testing. The difference between V0 and Vmax is not significant in slow twitch fibres, 
but V0 is significantly greater than Vmax in fast twitch fibres.73 If both force and velocity is 
known, power output (W) can be calculated from the equation power = force x velocity 
(W = P x V). From this equation, it follows that single fibre power can be improved by 
increasing force, velocity, or both. Therefore, when contractile force decreases, power 
output could theoretically be maintained by an increase in shortening velocity.  
A single study compared maximal unloaded shortening velocity (V0) of muscle 
fibres from patients with DM to fibres from healthy controls.46 They found V0 to be 33 % 
higher in type I fibres from patients with DM, while no difference was found in V0 of type 
IIa fibres. They hypothesised that this may be a compensatory mechanism to maintain 
muscle power output in the face of the overall loss of force producing capacity which 
arose from muscle fibre atrophy. However, it should be noted that, in this study, single 
fibre maximal and specific force production in DM was not decreased compared to healthy 




4.2 Purpose of the study 
  Aims and objectives 
The aim of the study was to determine whether the power output of muscle fibres 
from patients with IIMs is maintained despite the disease process. As contractile force is 
decreased in fibres from patients with IIMs (see Chapter 3), maintenance of power output 
would require an increase in shortening velocity. In order to investigate this, in vitro single 
fibre contractility studies were performed to assess the maximum shortening velocity 
(Vmax) and calculate power output of single muscle fibres from patients with IIMs and 
healthy controls. The objectives of the study were: 
iii. To compare the maximum shortening velocity of single muscle fibres from 
patients with treatment-naïve IIMs to that of fibres from healthy volunteers. 
iv. To calculate and compare the power output of single muscle fibres from 
patients with treatment-naïve IIMs to that of fibres from healthy volunteers. 
 Hypothesis 
It was hypothesised that, in an attempt to maintain power output in the presence of 
decreased force generating capacity (see Chapter 3), the maximum shortening velocity 
(Vmax) of muscle fibres from patients with IIMs would be increased. However, since it can 
be anticipated that such an increase in shortening velocity will be limited by physical 
properties of the muscle fibres, it was furthermore hypothesized that this increase will only 
be able to partially compensate for the decreased force generating capacity, with a 




The sources, acquisition and storage of specimens were described in Chapter 2, 
while the preparation of specimens and the solutions for single fibre experiments were 
described in Chapter 3. The procedures relating to the mounting, stretching, capturing of 
digital images, measurement of fibre dimensions (including fibre length, diameter and 
sarcomere spacing) and calculation of CSA and SF were described in Chapter 3. Force-
clamp studies for determination of Vmax were performed on the majority of fibres (~70 %), 
while the remaining fibres were used for calcium sensitivity studies (see Chapter 5). 
 Determination of maximum velocity and power output 
Velocity measurement was performed on the Aurora Scientific 1400A 
permeabilised fibre test system (Aurora Scientific, Ontario, Canada). Experiments were 
performed based on previously reported protocols.73,94,119 After measurement of P0, as 
described in Chapter 3, the fibre was transferred back to the relaxing solution and allowed 
to relax and regain its initial length. Each fibre was then subjected to a series of isotonic 
force clamps to construct force-velocity curves. First, maximum activation in pCa 4.5 
solution was again obtained, after which the fibre was subjected to a set of four 
successive force clamps, each clamp lasting 150 ms. For example, for the first force 
clamp set, the force was held constant at 80 % of P0. After 150 ms, the fibre was allowed 
to shorten to the next pre-programmed isotonic load (55 % of P0), and the process and 
data recording was repeated. After a further two force clamps (30 % and 10 % of P0), 
while the fibre was still submerged in activating solution, it was subjected to a 2 ms 
shortening to 50 % of its original length, and then immediately re-stretched within 1 ms to 
its original length. This re-stretching procedure aided in preserving the fibre integrity when 
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subjected to the next force clamp series.120,121 Following this, the fibre was transferred 
back to the relaxing solution and again allowed to relax and regain its initial length. The 
process was repeated 3 times at different isotonic loads, yielding a total of 16 force clamps 
in 4 sets (Table 9). After measurements were performed, each fibre was placed in a 
plastic microfuge tube containing 90 µl sodium dodecyl sulphate (SDS) buffer, and stored 
at -20˚C. Determination of MHC composition was described in Chapter 3. 
For each fibre, the shortening velocity was determined from the last 50 ms of each 
force clamp (length change), from which the slope was plotted against the force (% of 
maximum). A non-linear regression curve using the Hill-equation (P+a)(V+b)=(P0+a)b 
(where P is force, V is velocity, P0 is maximum force and a and b are constants) was fitted 
to the data points. Maximum shortening velocity (Vmax), expressed as FL/s (fibre length 
per second) was calculated by extrapolating the data back to 0 % force (see Figure 16). 
Power output (W) was calculated from the shortening velocity and specific force 
parameters using the formula power = force x velocity (W = P x V) and expressed as 
kN/m2.FL/s. These values were used to construct composite velocity-force and power-
force curves, and ultimately determine maximum power output (Wmax) for each fibre, as 
well as optimal force (force at which Wmax is developed, Popt), expressed as percentage 
of P0 (Popt x 100/P0). Force clamp measurements were excluded from analysis if the force 
at maximal activation during the initial phase of the clamp dropped below 90 % of P0. In 
addition, measurements obtained at less than 10 % of P0 were also excluded from the 
analysis. Because three of the force clamps were performed at forces less than 10 % of 
P0 (see Table 9), this yielded a maximum of 13 velocity data points. Fibres that broke 
during any of the force clamp sets were excluded from analysis. 
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Force clamp set Sequence of isotonic loads (expressed as percentage of P0) 
No 1 80 %, 55 %, 30 %, 10 % 
No 2 60 %, 40 %, 15 %, 2 % 
No 3 75 %, 50 %, 25 %, 6 % 
No 4 70 %, 45 %, 20 %, 4 % 
 
Table 9. Isotonic load sequences of each set of force clamp measurements.  
Sets were performed in the same order (1 to 4) for each fibre. Each set consisted of 4 isotonic 
force clamps, performed in descending order. Isotonic loads are expressed as percentage of P0 
(maximum force). 
 
 Determination of MyHC composition 
The protocol for MyHC determination has been described in Chapter 3.  
 
 Statistical analysis 
The D’Agostino & Pearson normality test was used to test data for normality of 
distribution. Because none of the data sets displayed a normal distribution, the non-
parametric Mann-Whitney test was used to compare differences in means. Categorical 
data were analysed by means of the two-tailed Fisher’s exact test. Statistical analysis 
was performed using GraphPad Prism version 7 (GraphPad Software, La Jolla, 
California). For all parameters, mean ± SD was calculated, unless stated otherwise. 




Participants included four patients with IIMs (all female), and four healthy controls 
(two male). Participant details are summarised in Table 10. 
The IIM group consisted of one patient with PM, two with DM, and one with NAM. 
In the IIM group, 27 of 120 (23 %) fibres broke during force clamp testing (7 type I and 20 
type IIa) and were excluded from the analysis, while another 2 fibres were excluded from 
analysis because of insufficient or unreliable data points. Overall, 91 fibres were studied 
from patients with IIMs; this included 25 type I fibres, 58 type IIa fibres, and 8 hybrid fibres 
(4 I/IIa, 2 I/IIx and 2 IIa/IIx). In the control group, 19 from 129 fibres (15 %) broke and 
were excluded (13 type I, 1 type I/IIa and 5 type IIa), while 9 fibres were excluded because 
of insufficient or unreliable data points. A total of 101 fibres, consisting of 66 type I fibres, 
27 type IIa fibres, and 8 hybrid fibres (6 I/IIa, 1 I/IIa/IIx, and 1 IIa/IIx), were studied from 
the healthy control group. The difference between the two groups with respect to fibre 




 IIMs CONTROLS 
Age 47 (26-60) 33 (22-44) 
Gender 4F 2M, 2F 
Diagnosis 1 PM, 2 DM, 1 NAM Healthy, recreationally active 
Fibre number 91 (33 type I) 101 (74 type I) 
 
Table 10. Participant details.  
Age is reported as mean (range) in years. DM: dermatomyositis, PM: polymyositis, NAM: 
necrotising autoimmune myopathy, F: female, M: male. 
 
 Specific force 
When SF calculations were restricted to the subset of fibres that are included in the 
force clamp testing examined in this chapter, the results differed from those described in 
Chapter 3, where all fibres were analysed. For the present data set, while SF was 29% 
lower in type IIa fibres from IIM cases than controls (90 ± 38 kN/m2 vs. 126 ± 40 kN/m2; 
p=0.0001, power = 0.97), there was no difference between type I fibres from cases (91 ± 
40 kN/m2) and controls (92 ± 33 kN/m2; p=0.69, power = 0.05). This difference appears 
to be due to the fact that the type I fibres from IIM cases with the lowest SF were included 
in the group of fibres that were selected for Ca2+ sensitivity analysis. As can be seen in 
Table 13 (Chapter 5), SF of type I fibres was substantially lower (51%) in IIM cases as 
compared to healthy controls, whereas the difference was only 27% for type IIa fibres. As 
fibres were randomly selected for either force clamp testing or Ca2+ sensitivity, this is 
likely to be a chance finding. 
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 Maximum shortening velocity and power output 
Type IIx fibres and hybrid fibres were not analysed separately due to the small 
numbers of these fibres in the biopsies. For type I fibres, Vmax was 122 % higher in the 
IIM cases (1.40 ± 1.50 FL/s vs. 0.63 ± 1.10 FL/s; p<0.0001), while Wmax was 105 % higher 
(4.10 ± 5.20 kN/m2.FL/s vs. 2.00 ± 1.30 kN/m2.FL/s; p<0.001) compared to controls. For 
type IIa fibres, Vmax was 159 % higher in the IIM cases (2.00 ± 1.30 FL/s vs 0.77 ± 0.51 
FL/s; p<0.0001) and Wmax was 50 % higher (9.00 ± 4.90 kN/m2.FL/s vs. 6.00 ± 3.50 
kN/m2.FL/s; p<0.01) than control values. Figure 17 and Figure 18 provide a visual 
representation of the Vmax values, while Figure 19 and Figure 21 illustrates the velocity-
force relationships for both fibre types. 
 
Figure 17. Vmax of Type I and IIa fibres (means + SD).  




Figure 18. Power of Type I and IIa fibres (means + SD).  
Wmax: maximum power output, normalised to fibre CSA; SD: standard deviation. 
 
 Optimal force 
Wmax of type I fibres was obtained at 29 ± 9 % and 21 ± 7 % of P0 for healthy controls 
and IIM cases, respectively. In the case of type IIa fibres, Wmax was achieved at similar 
optimal forces as for type I fibres (27 ± 7 % and 22 ± 6 % for healthy controls and IIM 
cases, respectively). Fibres from IIM cases, both type I and IIa, were therefore able to 
develop maximum power output at lower relative force, with a resultant left shift in the 
power-force curve (Figure 20 and Figure 22). The difference was statistically significant 




Figure 19. Velocity-force curves of Type I fibres of cases (solid lines) and controls (dotted 
lines). 
Force is expressed as percentage of P0 (maximum force). 
 
Figure 20. Power-force curves of Type I fibres of cases (solid lines) and controls (dotted 
lines). 
Force is expressed as percentage of P0 (maximum force). 
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Figure 21. Velocity-force curves of Type IIa fibres of cases (solid lines) and controls 
(dotted lines).  
Force is expressed as percentage of P0 (maximum force). 
 
Figure 22. Power-force curves of Type IIa fibres of cases (solid lines) and controls 
(dotted lines). 




In order to test the hypothesis that shortening velocity of muscle fibres from patients 
with IIMs is maintained despite the disease process, in vitro single fibre studies were 
performed to assess force-velocity relationships and maximum shortening velocity of 
individual muscle fibres from patients with IIMs and healthy controls. The findings of the 
study suggest significantly higher maximum shortening velocity of fibres from patients 
with IIM. Furthermore, maximum power output was not only maintained, but was in fact 
higher compared to fibres from healthy controls. In addition, efficiency of muscle fibres 
from patients with IIM was increased, enabling them to develop peak power output at 
lower relative force. 
If the hypothesis that the higher Vmax is a mechanism to maintain power output is 
indeed correct, the mechanism behind this compensatory response is not clear. As 
mentioned in the introduction, Vmax is dependent on the rate of cross-bridge turnover, 
which appears to be an intrinsic property of each individual actin-myosin interaction.116-
118,4 
One possible mechanism that may explain the observed findings relates to passive 
tension. Passive tension in muscle has traditionally been thought to arise from connective 
tissue between muscle fibres, as well as the non-contractile elements of the fibres 
(sarcolemma and sarcoplasm).122 Collagen is a prominent component of fibrosis, which 
is often seen in IIMs.123 Although it often becomes visible on routine histological 
examination only in more advanced disease, it is likely to be present from early in the 
disease process. Collagen appears to be one of the main contributors to passive tension 
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originating from connective tissue in cardiac muscle,124 and is likely to have a similar 
effect in skeletal muscle. Although collagen is a component of the endomysium, skinned 
fibres contain small amounts of collagen. However, in a recent study of skinned fibres 
from muscular dystrophy with myositis (mdm) mice, mutant fibres contained 7.9 ± 3.5 % 
collagen vs. 0.3 ± 0.1 % in control fibres.125 This finding suggests that collagen may 
contribute to mechanics at a fibre level, even though it is a component of the extracellular 
matrix. Recently, evidence has emerged that an important component of passive tension 
arises from the sarcomere, in particular the protein titin.126 Whitehead et al. (2001) 
showed that passive tension in muscle rises after muscle injury due to repeated eccentric 
contractures. They suggested that this rise in passive tension was the result of injury-
induced calcium-mediated contracture.127 Furthermore, single muscle fibre studies in 
facioscapulohumeral dystrophy (FSHD) have shown that both passive force and calcium 
sensitivity were increased, while myofilament lattice spacing was decreased (suggesting 
titin stiffening).20 The authors hypothesised that titin stiffening is a mechanism to 
compensate for muscle weakness in FSHD by increasing the calcium sensitivity of the 
sarcomeres. Although the pathogenesis of FSHD and IIMs is different, it is possible that 
similar compensatory mechanisms exist across the spectrum of muscle disorders, 
including the IIMs. 
Interestingly, increased Vmax has also been illustrated in nervous system conditions 
without direct muscle fibre damage, such as spinal cord injury and amyotrophic lateral 
sclerosis,88,90 as well as chronic unloading of muscle, like prolonged bed rest112,74 and 
space flight.128 In the case of prolonged bed rest, the increased V0 was associated with a 
decrease in maximum SF, whereas SF was not affected in spinal cord injury. Moreover, 
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in contrast to the findings in FSHD,20 passive tension was not increased in muscle fibres 
from patients with spinal cord injury. Matters are further complicated by reports of 
increased V0 in response to certain types of strengthening exercise, a contrasting 
physiological stimulus in terms of muscle activation.119  
In addition to an increase in passive tension, there are other potential mechanisms 
to increase Vmax  which require consideration. Firstly, differences in MyLC isoform content 
and phosphorylation could theoretically affect V0. In the rat, variability of Vmax in fibres with 
similar MyHC content is related to MyLC isoform content, with higher velocity correlating 
with a higher alkali MLC3f content.129,130 However, a similar effect of the MyLC isoform 
on shortening velocity in human fibres has not been demonstrated in a number of 
conditions including normal physiological conditions,131 space flight,128 endurance 
training84 and aging.74 Interestingly, in rats, the MyHC isoform that seems most sensitive 
to MyLC isoform variation is IIb. While this is the predominant isoform in rats, it is absent 
or only minimally expressed in human skeletal muscle,8 which may partially explain the 
fact that maximum shortening velocity in humans appeared to be insensitive to MyLC 
variation. Post-translational modification of myosin, in particular phosphorylation of 
regulatory MyLC, also does not appear to influence maximum shortening velocity.108,132 
Secondly, the influence of the mechanical performance of myosin molecules on 
shortening velocity should be considered. The sliding velocity of actin over myosin at zero 
load is dependent on the rate of cross-bridge turnover, and potentiation of this interaction 
could theoretically influence shortening velocity. The velocity at which myosin 
translocates actin filaments can be measured by means of the in vitro motility assay 
(IVMA). This method allows direct observation of the movement of a single fluorescently 
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labelled actin filament as it glides over a myosin-coated glass surface, and eliminates 
passive tension from the experimental set-up.133 To date, no IVMA investigations of 
muscle fibres from patients with IIMs have been performed, but decreased sliding 
velocities have been demonstrated in diaphragmatic and cardiac muscle of dystrophic 
mice.134,135 In addition, although immobilization was associated with increased maximum 
shortening velocity, it did not affect the actin sliding velocity as assessed by IVMA.74 This 
assay would be invaluable to further investigate the mechanisms behind the increased 
maximum shortening velocities observed in the current study, as a normal motility assay 
will support the contribution of passive tension, and vice versa. 
An interesting finding of this study is that power output of fibres from patients with 
IIM is not only maintained, but actually increased, suggesting that the increase in Vmax is 
of a higher magnitude than the decrease in force generation. Despite this response, 
clinical weakness still develops, emphasising the relative importance of force production 
compared to shortening velocity in muscle function. It should also be noted that, despite 
the theoretical advantages of increased shortening velocity, it is entirely possible that the 
observed response is an unintended consequence, rather than a true compensatory 
mechanism. In order to clarify this, repeat single fibre force and velocity measurements, 
performed after resolution of weakness with treatment, will be informative. Decreased or 
normalisation of maximum shortening velocity, in parallel with increase or normalisation 





This study has a number of potential limitations. Firstly, the same limitations 
discussed in the chapter on force measurement (Chapter 3) are applicable, namely the 
pooling of different disease entities in the IIM group and an incomplete matching for sex 
and age. However, as for force measurement, these limitations are unlikely to have 
significantly influenced the results, for reasons as discussed in Chapter 3. In addition, it 
should be noted that a few studies suggested a decrease and not an increase in maximum 
shortening velocity with age.74,114 The higher median age in the IIM group in this study 
therefore makes the findings even more convincing. 
 
4.6 Conclusion 
The findings of this study suggest that compensatory responses to maintain power 
output occur in muscle of patients with IIMs. These responses include increased 
maximum shortening velocity as well as improved efficiency, and appear to be present in 
both type I and IIa fibres. The mechanism underlying this response is unclear, but may 
be related to increased passive tension, increased rate of cross-bridge turnover, or a 




5 THE RELATIONSHIP BETWEEN FORCE AND CALCIUM 
CONCENTRATION OF SINGLE MUSCLE FIBRES FROM PATIENTS 
WITH IDIOPATHIC INFLAMMATORY MYOPATHIES 
______________________________________________________________________ 
 
5.1 Introduction and background 
As discussed in chapter 1, contraction of muscle fibres is dependent on a sufficient 
supply of intracellular calcium (Ca2+), which acts as a regulatory factor. In vivo, membrane 
depolarization leads to an influx of Ca2+ ions via voltage-gated Ca2+ channels, in turn 
leading to opening of Ca2+ channels (ryanodine receptors) in the SR (SR). This process 
ensures the large and rapid supply of Ca2+ required for contraction. Myosin-actin 
interaction, and hence the generation of force, is directly dependent on the 
Ca2+ concentration.136-138 At very low Ca2+ concentrations, no force is generated, while 
steadily increasing Ca2+ concentrations lead to increased force development. However, 
when all Ca2+-binding sites on troponin are occupied, this relationship exhibits a 
saturation effect, and increasing Ca2+ concentrations do not result in a further increase in 
force production. 
Muscle fibre force production in response to different intracellular 
Ca2+ concentrations can be evaluated in vitro by means of single fibre Ca2+ sensitivity 
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measurements. These are accomplished by submerging single permeabilised muscle 
fibres into solutions containing different concentrations of free Ca2+ ions and measuring 
maximum force development at each concentration. Utilising this technique, the 
relationship between force production and Ca2+ concentration has been shown to follow 
a sigmoidal curve (Figure 23), with maximal force production at pCa 4.6.139  
Ca2+ sensitivity of skeletal muscle is dependent on the complex formed by three 
troponin (Tn) subunits: inhibitory TnI, tropomyosin-binding TnT, and Ca2+-binding TnC.140 
A study by Moss et al. (1986) suggested that TnC plays a central role in the force / pCa 
relationship of skeletal muscle fibres.141  As opposed to the slow TnC isoform, which has 
one Ca2+ binding site, the fast isoform has two, which hypothetically confers the fibre a 
lower sensitivity to Ca2+. It has also been shown that TnT plays a central role in Ca2+ 
sensitivity by regulating actomyosin ATPase activity.142 Taken together, these findings 
provide a theoretical framework for the reported difference in Ca2+ sensitivity between 
type I and type II fibres.143,84 
However, Ca2+ sensitivity of muscle fibres may also be influenced by a number of 
physiological factors. Higher temperatures decrease Ca2+ sensitivity (curve shifts to the 
right),144,145 while plyometric exercise and osmotic compression lead to an increase in 
Ca2+ sensitivity (left shift of the curve).143,146 The exact mechanism behind such changes 
in Ca2+ sensitivity is not clear. The increased Ca2+ sensitivity after plyometric exercise 
does not appear to be related to differential TnT isoform expression, but the role of other 
proteins of the contractile apparatus remains to be explored. A likely mechanism for the 
temperature dependence is an effect on the binding of Ca2+ ions to TnC,144 while a 
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decrease in interfilament spacing may contribute to increased Ca2+ sensitivity in osmotic 
compression.146 
In addition, pathological processes may potentially influence Ca2+ sensitivity in 
either direction. On one hand, it is possible that Ca2+ sensitivity may be improved as a 
compensatory mechanism in muscle disorders. For example, Lassche et al. (2013) 
studied permeabilised single muscle fibres from patients with FSHD, and found 
decreased maximal force generation and increased passive force and Ca2+ sensitivity in 
type II fibres.20 They hypothesized that these changes represented compensatory 
mechanisms. As opposed to the viewpoint that Ca2+ sensitivity is compensatory, it is 
conceivable that certain disease processes might actually lead to a decrease in Ca2+ 
sensitivity by interfering with the response of the contractile apparatus to increasing 
intracellular Ca2+ concentrations. In IIMs, as shown in Chapter 3, sarcomeric force 
production appears to be decreased. Whether IIMs are also associated with changes in 
Ca2+ sensitivity has not been investigated. As discussed before, TNF-α appears to be a 
major role player in the development of weakness in these conditions and may exert this 
effect via a number of mechanisms, including reversible oxidative inhibition of myosin 
ATPase or TnC.42 However, in animal studies, TNF-α decreased sarcomeric force 
production, but had no effect on Ca2+ sensitivity.91 Thus, whether Ca2+ sensitivity of 
muscle fibres is altered in IIMs requires further exploration.  
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Figure 23. Force / Ca2+ relationship obtained by measuring maximum force production of 
permeabilised single muscle fibres at different Ca2+ concentrations. 
 
5.2 Purpose of the study 
  Aims and objectives 
The aim of the study was to determine whether the sensitivity to intracellular Ca2+ 
is altered in muscle fibres from patients with IIMs compared to healthy controls. In order 
to investigate this, in vitro single fibre contractility studies were performed to assess the 




  Hypothesis 
As shown in Chapters 3 and 4, maximal force generation is decreased, while 
maximal shortening velocity and power output is increased in single muscle fibres from 
patients with IIMs. In view of similar findings in FSHD,20 it was hypothesised that Ca2+ 
sensitivity will be increased in fibres from patients with IIMs.  
 
5.3 Methods 
The sources, acquisition and storage of specimens were described in Chapter 2, 
while the preparation of specimens was described in Chapter 3. The procedures relating 
to the mounting, stretching, capturing of digital images, measurement of fibre dimensions 
(including fibre length, diameter and sarcomere spacing) and calculation of CSA and SF 
were also described in Chapter 3. 
 
  Solutions for force measurement 
The preparation of relaxing solution and maximally activating solution was 
described in Chapter 3. In summary, the relaxing solution contained 7 mM EGTA, 20 mM 
Imidazole, pH 7.00, 5.08 mM ATP, with a total ionic strength of 180 mM, and –log 
concentration of free ions amounting to pMg 3.00, pCa 9.00 and pATP 2.40. The 
maximally activating solution contained 7 mM EGTA, 20 mM imidazole, pH 7.00, 5.08 mM 
ATP, 14.5 mM creatine phosphate and 200 U/ml creatine kinase, with a total ionic strength 
of 180 mM. The –log concentration of free ions amounted to pMg 3.00, pCa 4.50 and 
pATP 2.40. In addition to these two solutions, six sub-maximally activating solutions, each 
identical to the maximally activating solution but with different Ca2+ concentrations ranging 
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from pCa 6.8 to pCa 5.1, were prepared. The different solutions were added to the wells 
of the permeabilised fibre test system in random order, as shown in Table 11. 
 
Well no. Solution pCa 
1 Relaxing solution 9.0 
2 Submaximal activating solution 6.8 
3 Submaximal activating solution 5.8 
4 Maximum activating solution 4.5 
5 Submaximal activating solution 5.1 
6 Submaximal activating solution 6.2 
7 Submaximal activating solution 5.4 
8 Submaximal activating solution 6.0 
 
Table 11. Distribution of the different solutions for force measurements at different Ca2+ 
concentrations in the wells of the permeabilised fibre test system.  
The maximum and submaximal activating solutions differed from each other only with respect to 
the Ca2+ concentrations. Details about the different solutions are provided in APPENDIX A. 
 
  Protocol for force measurements at different Ca2+ concentrations 
Calcium sensitivity measurement was performed on the same Aurora Scientific 
1400A permeabilised fibre test system described in Chapters 3 and 4. Isometric force 
production at different Ca2+ concentrations was measured by transferring the muscle fibre 
segment rapidly between the different wells of the plate, each containing a different 
solution (Table 11). First, baseline force in the relaxing solution was recorded for at least 
1 minute. The fibre was then rapidly transferred to well no 2, containing submaximal 
activating solution with a pCa of 6.8. The fibre was maintained in the activating solution 
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until a steady state of maximum force was reached, after which it was transferred back to 
the relaxing solution (well no 1), and allowed to relax and regain its initial length. The 
procedure was repeated for each of wells 3 through 8, and maximal developed force 
recorded at each pCa. The force developed at submaximal activating levels (relative 
force; Pr) was expressed relative to maximum force obtained at a pCa of 4.5 (P0). 
 
  Calculation of single fibre Ca2+ sensitivity 
For each fibre, the force – Ca2+ relationship was evaluated using an iterative 
nonlinear curve-fitting procedure based on the Marquardt–Levenberg algorithm. pCa50%, 
the Ca2+ concentration at which half-maximal activation occurs, was calculated based on 
the Hill equation: Pr = pCan/(pCa50%n + pCan), where n is the Hill coefficient, an indicator 
of the slope of the relationship.147 All calculations were performed using GraphPad Prism 
version 7 (GraphPad Software, La Jolla, California). Occasionally, force values were 
obtained that were lower than the value at the preceding (lower) Ca2+ concentration. The 
reason for these outlying values was not clear, but no physiological explanation was 
evident, as force production increases with increasing Ca2+ concentration (up to pCa 4.5). 
These data points were therefore excluded from analysis because of the profound effect 
a single outlying value has on the shape of the curve.  Fibres were excluded from analysis 
if less than 5 data points (excluding the zero value at pCa 9.0) could be used for the 
curve-fitting procedure. 
  Determination of MyHC composition 
The protocol for MyHC determination has been described in detail in Chapter 3. 
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  Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 7 (GraphPad 
Software, La Jolla, California). For all parameters, mean ± SD was calculated, unless 
stated otherwise. The D’Agostino & Pearson normality test was used to test data for 
normality of distribution. The unpaired t test with Welch’s correction was used to compare 
means where data sets displayed a normal distribution, while the non-parametric Mann-
Whitney test was used for data sets with non-normally distributed data. Statistical 
significance was set at P<0.05. 
 
5.4 Results 
Participants included consisted of five patients with IIMs (all female), and five 
healthy controls (one male). Participant details are summarised in Table 12. 
 
 GROUP 
 IIMs CONTROLS 
Age 48 (26-60) 28 (22-44) 
Gender 5F 1M, 4F 
Diagnosis 1 PM, 2 DM, 2 NAM Healthy, recreationally active 
Fibre number 49 (17 type I) 41 (11 type I) 
 
Table 12. Participant details. Age is reported as mean (range) in years.  





In the IIM group, 9 out of 58 (16 %) fibres (6 type I, 2 type IIa and 1 tipe I/IIa)  were 
excluded from analysis because of insufficient data points, while 4 out of 45 (9 %) fibres 
(1 type I, 1 type IIa and 2 type I/IIa) were excluded in the control group. There was no 
difference in CSA between the two groups for any of the fibre types, but SF was 
significantly lower in type I and IIa fibres of IIM cases. 
Ca2+ sensitivity analysis of type I fibres showed no difference in pCa50% between 
the two groups (Table 13 and Figure 24) (power = 0.06). However, for type II fibres, as a 
whole, there was a small but statistically significant difference in mean pCa50%, which was 
0.22 log units higher in IIM cases (power = 0.89), indicating an increase in Ca2+ sensitivity. 
Similarly, when type IIa fibres were analysed separately, pCa50%, was 0.24 log units 
higher in IIM cases (power = 0.75), with the difference remaining statistically significant 
(Table 13). The resultant left shift of the curve is illustrated in Figure 25. When comparing 
type I to type II fibres within each group, pCa was 0.12 log units higher in type II than type 
I fibres from IIM cases (p = ns), but 0.14 log units higher in type I than type II fibres from 






IIM Controls p-value 
Type I 
   CSA (µm2) 
   SF (kN/m2)    
   pCa50% 
 
(N=17) 
4150 ± 2109 
58 ± 28 
5.53 ± 0.25 
(N=11) 
3847 ± 1688 
118 ± 37 





Type II (all) 
   CSA (µm2) 
   SF (kN/m2) 
    pCa50% 
(N=24) 
4802 ± 2414 
94 ± 45 
5.65 ± 0.31 
(N=29) 
4656 ± 2171 
108 ± 54 







   CSA (µm2) 
   SF (kN/m2) 
   pCa50% 
 
(N=16) 
5113 ± 2572 
80 ± 26 
5.66 ± 0.37 
 
(N=28) 
4574 ± 2165 
110 ± 54 







Table 13. Force - pCa relationships of different fibre types of IIM cases and healthy 
controls. 
Values represent means ± SD. MyHC: myosin heavy chain; CSA: cross-sectional area; SF: 
specific force; pCa50%: concentration at which half-maximal activation occurs. Because of a lack 





Figure 24. Force - pCa relationship of type I fibres of IIM cases (solid line) and healthy 
controls (dashed line). 
The curves were constructed by calculating mean Pr (force developed at submaximal activating 
levels relative to maximum force obtained at a pCa of 4.5) at each pCa for each group, and 
performing an iterative nonlinear curve-fitting procedure. 
 
 
Figure 25. Force - pCa relationship of type IIa fibres of IIM cases (solid line) and healthy 
controls (dashed line). 
The curves were constructed by calculating mean Pr (force developed at submaximal activating 
levels relative to maximum force obtained at a pCa of 4.5) at each pCa for each group, and 




The relationship between intracellular Ca2+ concentration and force production 
during contraction has been studied in animal and human subjects under different 
physiologic conditions.139,144,143,146 However, data on Ca2+ sensitivity in muscle disorders 
are limited to a single study of FSHD.20 The present study investigated the force – pCa 
relationship in permeabilised muscle fibres from patients with IIMs compared to healthy 
controls. The findings of the study suggest a statistically significant increase in Ca2+ 
sensitivity of type IIa fibres of IIM cases, with a 0.24 log unit increase in pCa50%. Although 
this difference appears small, calculation of effect size reveals a Cohen’s d of 0.85, which 
is regarded as a large effect size.148 However, compared to the differences in shortening 
velocity and power output between IIM cases and controls described in Chapters 3 and 
4, an increase of this magnitude is relatively minor, and unlikely to contribute significantly 
to the changes in velocity and power. Interestingly, in IIM cases, the Ca2+ sensitivity of 
type II fibres was higher than type I fibres (although the p-value was non-significant). This 
is in contrast to findings in healthy controls, both in the present study and previous reports, 
in whom Ca2+ sensitivity is higher in type I fibres.143,84 This finding lends more support to 
the notion that only the Ca2+ sensitivity of type II fibres, in particular type IIa fibres, is 
altered in IIMs. 
If the findings of the present study can be confirmed in a larger cohort, the 
mechanisms underlying such an alteration in Ca2+ sensitivity remains to be explored. In 
contrast to its possible effect on force production, TNF-α is unlikely to play a direct role in 
the modification of force – pCa relationships. Although chemically permeabilised muscle 
fibres from TNF-α treated animals had lower maximal Ca2+-activated force, no change in 
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Ca2+ sensitivity was observed.91 However, contractility studies were only performed on 
muscle up to 48 hours after TNF-α injection, and therefore a delayed effect of TNF-α on 
Ca2+ sensitivity could not be excluded. Another possible mechanism involves a decrease 
in myofilament lattice spacing, which was demonstrated in muscle fibres from patients 
with FSHD, together with an increase in Ca2+ sensitivity.20 The authors ascribed both 
these findings to titin stiffening, based on previous reports.149 Interestingly, the increased 
Ca2+ sensitivity seen with osmotic compression is also associated with a decrease in 
myofilament lattice spacing.146,150 Based on the above, it is conceivable that decreased 
myofilament lattice spacing, regardless of the mechanism by which this is accomplished, 
may contribute to increased Ca2+ sensitivity. Whether myofilament lattice spacing is 
altered in IIMs has not been investigated and warrants consideration. 
Any hypothesis regarding the potential mechanisms should take into account the 
fact that the increase in Ca2+ sensitivity was only evident in type II, and not type I fibres. 
A potential explanation for this involves the troponin complex (see Introduction). If 
inflammation can, directly or indirectly, lead to differential TnT or TnC isoform expression 
(i.e. slow TnT or TnC isoform expression in type II fibres instead of the fast isoform), it 
could lead to an increase in Ca2+ sensitivity. Such a mechanism would also account for 
the absence of an alteration in type I fibre Ca2+ sensitivity, as the slow isoforms are 
already present in this fibre type and Ca2+ sensitivity has therefore reached a ceiling. 
Consideration should also be given to the possibility that the increased Ca2+ 
sensitivity is a consequence of immobilisation, and not directly related to the disease 
process. However, in a study investigating the effect of short-term (2 weeks) 
immobilisation on contractile properties of young and old individuals, Hvid et al. (2011) 
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found a decrease in Ca2+ sensitivity.151 Similarly, Yamashita-Goto et al. (2001) showed 
decreased Ca2+ sensitivity after 2 and 4 months of bed rest (type I and II fibres were not 
analysed separately),112 while Widrick et al. (1998) found decreased Ca2+ sensitivity in 
type I soleus muscle fibres after 17 days of bed rest (no type II fibres were analysed).111 
In contrast, Malisoux et al. (2007) found no alteration in Ca2+ sensitivity of any fibre type 
from long-term paralysed (spinal cord injury) patients.90 The effect of immobilisation on 
Ca2+ sensitivity, if any, therefore appears to be the opposite of what the present study 
found in IIMs, excluding immobilisation as a potential mechanism. 
 
Study limitations 
This study has a number of potential limitations. Firstly, because Ca2+ sensitivity 
was only performed on a portion of the muscle fibres subjected to force measurement, 
the study lacks sufficient numbers and statistical power. However, despite this, the 
difference between the two groups was still statistically significant for type IIa fibres, with 
a relatively large effect size. A second limitation is incomplete matching for sex and 
especially age in the control group, with the mean age in the IIM group being substantially 
higher. Age difference between the two groups is, however, unlikely to have influenced 
the results. In a study by Lamboley et al. (2015), the difference in pCa50% was ~ 0.05 log 
units lower in type IIa fibres from old (70 ± 4 years) than young (22 ± 3 years) 
participants.152 In another study, Hvid et al. (2011) found no difference in Ca2+ sensitivity 
of type I or IIa fibres between young (24 ± 1 years) and old (67 ± 2 years) participants.151 
The effect of age on Ca2+ sensitivity therefore appears to be rather small or non-existent. 
If indeed present, Ca2+ sensitivity appears to be slightly higher in young individuals, 
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making the findings of the present study more robust, in view of the higher mean age of 
the IIM group. 
 
5.6 Conclusion 
Measurement of force – pCa relationship provides information on the sensitivity of 
the contractile apparatus to submaximal activating Ca2+ concentrations. The findings of 
this study suggest that the Ca2+ sensitivity of type IIa fibres from patients with IIMs is 
increased, while type I Ca2+ sensitivity is not altered. It is conceivable that the increased 
sensitivity of type IIa fibres serves as a mechanism to compensate for weakness and 




6 INTERPRETATION OF FINDINGS AND FUTURE DIRECTIONS 
____________________________________________________________ 
 
6.1 Interpretation of findings 
Although extensive research into the immunological and qualitative morphological 
characteristics of idiopathic IIMs has been performed, little is known about the 
mechanism(s) by which these result in the development of weakness. In contrast to 
muscular dystrophies, where inherited abnormalities of structural proteins are known to 
lead to dysfunction of the contractile apparatus or its supportive structures, the 
explanation for weakness in IIMs is relatively obscure. The aim of this project was to 
investigate the functional alterations and quantitative morphological changes in muscle 
from patients with IIMs, in order to gain a better understanding of the potential 
mechanisms underlying the development of muscle weakness and fatigue in this group 
of disorders. 
As discussed in Chapter 1 (section 1.1.2), muscle weakness can theoretically 
develop either due to a decreased number of fibres contributing to contraction, or 
impaired contractile function of individual fibres. The different components of these two 
main mechanisms, and how the findings of this research project addressed each of them, 
is summarised below. 
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 Decreased number of fibres contributing to contraction 
The number of fibres contributing to contraction can be decreased either due to a 
loss of fibres as a result of necrosis, failure of conduction at the neuromuscular junction 
(NMJ), or loss of sarcolemmal excitability with resultant non-contraction due to the 
inability to generate an action potential. With regards to myofibre necrosis, the findings 
from this study (Chapter 2) and others suggest that the number of necrotic fibres in IIM 
biopsies (~ 1%) is insufficient to explain the degree of weakness.39 Contrary to muscular 
dystrophies, there is also very little, if any, fibrosis visible on routine histological 
examination of IIMs, making extensive necrosis highly unlikely. Failure of conduction at 
the NMJ or the sarcolemma was not directly assessed in the present study, but the 
decreased force production illustrated by in vitro single muscle fibre contractility studies 
(Chapter 3) cannot be explained by conduction failure. One of the strengths of in vitro 
contractility studies is that it eliminates the role of the NMJ and sarcolemma by the direct 
intracellular provision of Ca2+ and ATP required for contraction, instead of relying on 
sarcolemmal depolarisation for Ca2+ release from the SR. Furthermore, motor nerve 
conduction studies, which assess the functional electrical integrity of the motor nerve, the 
NMJ, and muscle membrane, are typically normal in IIMs.153 Based on these 
observations, a decrease in the number of contracting muscle fibres does not appear to 
be the major mechanism underlying weakness in IIMs, although a minor contribution 
cannot be wholly excluded. 
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 Impaired contractile function of individual fibres 
As discussed in Chapter 1, factors that hypothetically may lead to impaired 
contractile function of individual fibres include structural abnormalities of proteins involved 
in contraction, functional impairment of contraction (i.e. myofibrillary dysfunction), and 
deficient cellular energy production or calcium (Ca2+) supply. Based on the findings of the 
present study, it is highly unlikely that cellular energy production or Ca2+ availability play 
a significant role in the impairment of contractile function. ATP, the main source of energy 
required for contraction, together with Ca2+, are supplied in sufficient quantities in the 
activating solution. Because the sarcolemma is permeabilised, these chemicals are freely 
available to the muscle fibre during submersion into the activating solution. Therefore, if 
force production is shown to be impaired when performing contractility studies (Chapter 
3), the impairment cannot be ascribed to availability of any of these chemicals. Although 
the activities of enzymes involved in cellular energy production were shown to be 
decreased (Chapter 2), this is more likely to be a consequence of the disease process 
(e.g. related to physical inactivity of the patients), rather than a contributing factor to 
weakness and fatigue. The activities of the four enzymes measured were similar to 
sedentary values, and the controls were in range with recreational and trained 
athletes.68,154 
The impaired maximum force production illustrated in Chapter 3 can therefore best 
be explained by one or more abnormalities of the contractile apparatus. Whether these 
abnormalities are structural or functional is not clear, and hypotheses for both 
mechanisms could be generated. Currently, data from a number of animal studies favour 
a functional impairment mediated by TNF-α, probably via increased oxidative stress, as 
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discussed in Chapter 3. These data include impaired contractility within hours of TNF-α 
infusion or incubation,42,44,43,91,41 partial blocking of this effect on contractility by 
cyclooxygenase inhibition,43 increased intracellular oxidant activity in response to TNF-α 
administration,91,41 and inhibition of both the oxidant activity and the effect on contractility 
by incubation with an antioxidant.91,41 Although other mechanisms for impairment of 
contractile function,  such as myosin ATPase inhibition and alteration of actin-myosin 
interactions are theoretically possible, there is currently no data to support such 
mechanisms. 
In addition to maximum force production, the present study also investigated 
maximum shortening velocity, power output, and Ca2+ sensitivity of muscle fibres from 
individuals with IIMs. Both maximum shortening velocity and power output were 
significantly higher not only in type I but also in IIa fibres from IIM cases compared to 
controls, while Ca2+ sensitivity was increased only in type IIa fibres. While the significance 
of altered calcium sensitivity is less clear, the increase in maximum shortening velocity is 
likely to represent a compensatory mechanism to maintain power output in the presence 
of impaired force production. However, it should be noted that these mechanisms appear 
only to be partially effective in limiting weakness, as evidenced by the prominent 
symptomatology these patients present with. 
Lastly, consideration should be given to the effects of muscle disuse/inactivity on 
the contractile properties of muscle fibres. As discussed in the preceding chapters, 
immobilisation has been shown to affect force production, shortening velocity, power 
output and Ca2+ sensitivity.74,90,111,112 It is important to note, however, that there is a 
significant difference in the extent of disuse/inactivity between participants in the current 
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study (mobile, but decreased activity due to weakness and fatigue) and those in the 
referenced studies (complete immobilisation, bed rest or chronic spinal cord injury). It is 
therefore not clear whether the findings of the current study could, even partially, be 
explained by disuse/inactivity. In order to investigate this further, the effect of exercise on 
contractile properties of muscle fibres from IIM patients will need to be investigated while 
controlling for the effects of co-interventions, e.g. corticosteroid therapy. 
 
6.2 Future directions 
The present study was designed to investigate whether the contractile properties of 
muscle fibres from individuals with IIMs are altered, and the results of the study could 
form the basis for future research into possible explanations for the changes in contractile 
properties. The main finding of the study, impairment in maximum force production, 
requires further investigation of the underlying mechanisms, in particular the role of 
inflammatory cytokines such as TNF-α. A study assessing the correlation between TNF 
receptor (TNFR) expression and contractile properties of muscle fibres from individuals 
with IIMs would be well suited to investigate this issue, as well as confirm (or refute) the 
findings of this study. Ideally, muscle tissue should be obtained from patients on at least 
two occasions: before and after treatment with corticosteroids. As corticosteroids have 
been shown to inhibit secretion of TNF-α by monocytes and decrease serum levels of 
soluble TNFR1 and TNFR2, the response to this treatment may prove to be a valuable 
clue.54,55 In addition, quantification of myosin concentration may be appropriate, as a 
linear correlation with force production has been shown in aging and immobilisation.74 
The possibility that inflammation may lead to a decrease in myosin concentration has not 
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been investigated, and is worth pursuing, although the confounding influence of inactivity 
due to the disease may prove problematic when interpreting the results. 
The impaired force production by muscle fibres from IIM cases shown here, as well 
as in other muscle disorders,18-20 is assumed to be a direct consequence of the disease 
process. However, although a less likely explanation, the possibility that the impaired 
force production serves to protect the fibre from irreversible damage should perhaps also 
be considered. A similar situation may be noted in muscle dystrophies, where fibres that 
are dystrophin deficient lack structural integrity, compared to normal muscle fibres.155 
Since maximal contraction exposes the fibre to substantial shearing forces, limiting force 
production may therefore serve to protect the structural integrity of the fibre. Although the 
structural integrity of muscle fibres has not been investigated in IIMs, a personal 
observation of this investigator is that fibres from IIM cases are substantially more fragile 
than those from healthy controls. This observation should be considered in future 
research. 
A number of additional findings from the present study are worthy of further 
investigation. Firstly, as discussed in Chapter 2, the higher proportion of type II fibres 
(which are capable of higher force and power production) in IIM cases may be a 
compensatory mechanism. Future studies should first seek to confirm or refute this finding 
in a larger sample of newly diagnosed, treatment-naïve cases. Secondly, a striking finding 
is the significantly higher maximum shortening velocities, and consequently power output, 
of both fibre types in IIMs. Although higher shortening velocities could be explained as a 
compensatory mechanism in an attempt to preserve power output, the response appears 
to be excessive and “overcompensating”, resulting in higher power output compared to 
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healthy controls. This observation raises the question whether the altered maximum 
shortening velocity is indeed a compensatory mechanism, or rather an unintended 
consequence of the disease process mediated by, for example, increased passive 
tension due to collagen deposition or titin stiffening (see Chapter 4). In order to investigate 
the mechanisms underlying the observed changes in shortening velocity further, passive 
force measurements can be performed on permeabilised muscle fibres. If passive tension 
is indeed found to be abnormal, X-ray diffraction studies and quantification of collagen 
content may be able to identify titin stiffening or increased collagen content (or both) as 
causative. In addition to passive tension, an increase in actin sliding velocity over myosin 
should be considered as a mechanism by which maximum shortening velocity can be 
increased. The in vitro motility assay is able to assess this, and should be included in 
future research. 
 
6.3 Concluding remarks 
As is evident from the above, the scope for research into the mechanism(s) by 
which weakness develops in IIMs is extensive. Ideally, such research should include 
enough patients to investigate the above issues, not only in IIMs as a group, but also in 
each of the different disease entities separately, for reasons already alluded to. However, 
in view of the rarity of these disorders, this may prove difficult. In addition, the laboratory 
techniques utilised, e.g. permeabilised single fibre studies, are time-consuming and 
technically demanding, and availability is limited to a few centres with special interest in 
these techniques. 
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However, despite the relatively low impact on society due to their rarity, the impact 
of these disorders on the individual is immense, and they deserve to be investigated with 
the same urgency as other disorders. Furthermore, unravelling mechanisms of disease 
such as these, not only has the potential to improve the lives of those affected by the 
disease, but inevitably, also reveal scientific principles with broader implications to both 
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9 APPENDIX A 
 
Notes & Ackowledgements 
 
The methods described here are from Bottinelli, Betto, Schiaffino & Reggiani, 1994; 
Bottinelli, Schiaffino & Reggiani, 1991; Pansarasa et al., 2008.  
 
Technical expertise and advice has been provided by Matthew Borkowski (Aurora 
Scientific Inc.) and Dr. Niels Ørtenblad (University of Southern Denmark).  
 






Name Company Cat # Mr Stock 
ATP-Na2·xH2O Sigma A-2383 551.1 0.1 M 
CaCl2 Sigma C-2661 110.98 0.1 M 
Caffeine Sigma C-0750 194.19 0.1 M 
Creatine kinase Sigma C-3755  315U/mg 
Creatine phosphate-Na2·4H2O Roche/Sigma 621722/P-6915 327.2 0.5 M 
DTT Boehringer  154.3 0.1 M 
EGTA Sigma E-4378 380.4 0.1 M 
Imidazole, pKa = 6.95 at 25 °C Sigma I-0125 68.08 1.0 M 
KCl Sigma P9541 74.55 1.0 M 
KH2PO4 Sigma P-9791 136.09 0.5 M 
KOH Sigma P-6310 56.11 5.0 M 
Mg-acetate·4H2O Sigma M-5661 214.5 0.5 M 
MgCl2 ·6H2O Sigma M-0250 203.3 0.5 M 
Propionic acid Sigma 402907 74.08 13.4 M 
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CALCULATIONS FOR STOCK SOLUTIONS 
0.1 M ATP-Na2 
Weigh off 55.1 mg and make up to 1 ml ddH2O. Store at -20 °C. 
 
0.1 M CaCl2 
Weigh off 0.555 g and make up to 50 ml ddH2O. Store at -20 °C. 
 
0.5 M Caffeine 
Weight off 0.971 g and make up to 10ml ddH2O. Store in fridge. 
 
0.5 M Creatine phosphate-Na2 
Weigh off 163.6 mg and make up to 1 ml ddH2O. Store at -20 °C. 
 
0.1 M EGTA 
Weigh off 0.951 g and make up to 25 ml ddH2O. Store at -20 °C. 
 
1.0 M Imidazole 
Weigh off 3.4 g and make up to 50 ml ddH2O. Store at -20 °C. 
 
1.0 M KCl 
Weigh off 3.73 g and make up to 50 ml ddH2O. Store at -20 °C. 
 
0.5 M Mg-acetate 
Weigh off 1.073 g and make up to 10 ml ddH2O. Store at -20 °C. 
 
0.5 M MgCl2  
Weigh off 1.0165 g and make up to 10 ml ddH2O. Store at -20 °C. 
 
5.0 M KOH 
Weigh off 14.03 g and make up to 50 ml ddH2O. 
 
0.5 M KH2PO4 
Weigh off 3.4 g and make up to 50 ml ddH2O. Store at -20 °C. 
 136 
 
Creatine Kinase (4000 U/ml) 
315 U/mg = 1 mg/ml = 315 U/ml   à 1 mg / 100 μl = 10 mg/ml = 3150 U/ml 
thus  10 mg/ml   = 3150 U/ml = x mg/ml  =  4000 U/ml x 10 mg/ml 
 x mg/ml 4000 U/ml    = 3150 U/ml 
= 12.70 mg in 1 ml ddH2O – only have 11.11mg, thus 11.11mg / 12.70mg/ml = 875 µl 
ddH2O 





Skinning solution (pH 7.00) 
Stock [Stock] For 10 ml For 50 ml [Final] 
K-Propionate 13.4 M 112 μl 560 μl 150 mM 
KH2PO4 0.5 M 100 μl 500 μl 5 mM 
Mg-acetate 0.5 M 100 μl 500 μl 5 mM 
EGTA 0.1 M 500 μl 2.5 ml 5 mM 
CaCl2 0.1 M 100 μl 500 μl 1 mM 
     
• Add a few drops ddH2O so that pH probe would be covered. 
• Adjust pH with 5.0 M KOH stirring continuously. 
 
• After adjustment, add the ATP. 
Stock [Stock] For 10 ml For 50 ml [Final] 
ATP·Na2 0.1 M 300 μl 1.5 ml 3 mM 
• QS to desired volume, check pH again and adjust accordingly. 
• Store at -20 °C in aliquots of 1 ml for 2 months and -87 °C for longer periods. 





This mix is used when new solutions are made. 
Add the following to make a 50 ml mix. 
SOLUTION [STOCK] VOLUME [FINAL] 
Imidazole 1 M 10 ml 200 mM 
EGTA 0.1 M 35 ml 70 mM 
dH2O  5 ml  
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Relaxing solution (pH 7.00) : Final ionic strength = 180 mM 
 
NB: Perform pH at 15 °C. 
 
Stock [Stock] Volume for 20 ml [Final]  
EGTA-Imidazole mix  2 ml 7 mM EGTA  
   20 mM Imidazole 
KCl 1.0 M 1521 μl   
MgCl2 0.5 M 220 μl 5.5 mM pMg = 3.00 
CaCl2 0.1 M 2.91 μl 0.02 mM pCa = 9.00 
     
• Add a few drops dH2O so that pH probe would be covered.  
• Adjust pH with 5.0 M KOH stirring continuously.  
  
• After adjustment, add the ATP and P-Creatine.  
Stock [Stock] Volume for 20 ml [Final]  
ATP·Na2 0.1 M 1017 μl 5.08 mM pMgATP = 2.4 
P-Creatine 0.5 M 580 µl 14.5 mM  
• Recheck pH and adjust accordingly. 
• Bring final volume to 20 ml with dH2O.  




Pre-activating solution (pH 7.00) : Final ionic strength = 180 mM 
 
NB: Perform pH at 15 °C. 
 
Stock [Stock] Volume for 20 ml [Final]  
EGTA 0.1 M 100 μl 0.5 mM  
Imidazole 1.0 M 400 µl 20 mM  
KCl 1.0 M 2033 µl   
MgCl2 0.5 M 213 μl 5.33 mM pMg = 3.00 
     
• Add a few drops dH2O so that pH probe would be covered.  
• Adjust pH with 5.0 M KOH stirring continuously.  
  
• After adjustment, add the ATP and P-Creatine  
Stock [Stock] Volume for 20 ml [Final]  
ATP·Na2 0.1 M 1.029 ml 5.14 mM pMgATP = 4.00 
P-Creatine 0.5 M 580 µl 14.5 mM  
• Recheck pH and adjust accordingly. 
• Bring final volume to 19 ml with dH2O, NOT 20 ml. 
• Store at -20 °C in aliquots of 1 ml for 2 months and -87 °C for longer periods. 





Activating solution (pH 7.00) : Final ionic strength = 180 mM 
 
NB: Perform pH at 15 °C. 
 
Stock [Stock] Volume for 20 ml [Final]  
EGTA-Imidazole mix  2 ml 7 mM EGTA  
   20 mM Imidazole 
KCl 1.0 M 1240 µl   
MgCl2 0.5 M 213 μl 5.33 mM pMg = 3.00 
CaCl2 0.1 M 1406 µl 7.032 mM pCa = 4.50 
     
• Add a few drops dH2O so that pH probe would be covered.  
• Adjust pH with 5.0 M KOH stirring continuously.  
  
• After adjustment, add the ATP and P-Creatine  
Stock [Stock] Volume for 20 ml [Final]  
ATP·Na2 0.1 M 1035 µl 2.66 mM pMgATP = 2.41 
P-Creatine 0.5 M 580 µl 14.5 mM  
• Recheck pH and adjust accordingly. 
• Bring final volume to 19 ml with dH2O, NOT 20 ml.  
• Store at -20 °C in aliquots of 1 ml for 2 months and -87 °C for longer periods. 




Varying pCa solutions : Final ionic strength = 180 mM 
 
NB: Perform pH at 15 °C. 
 
Stock [Stock] pCa pCa pCa pCa pCa pCa pCa pCa pCa Total 
required   6.8 6.5 6.2 6.0 5.8 5.4 5.1 4.9 4.7 
  µl µl µl µl µl µl µl µl µl ml 
EGTA-
Imidazole Mix 1000 1000 1000 1000 1000 1000 1000 1000 1000 9 
            
KCl 1 M 725 704 680 666 653 636 629 626 623 5.9 
MgCl2 0.5 M 109 109 108 107 107 107 106 106 106 1.0 
CaCl2 0.1 M 182 289 409 483 546 630 666 681 693 4.6 
            
• Add a few drops ddH2O so that pH probe would be covered. 
• Adjust pH with 5.0 M KOH stirring continuously. 
• After adjustment, add the ATP and P-Creatine. 
 
 [Stock] pCa pCa pCa pCa pCa pCa pCa pCa pCa  
  6.8 6.5 6.2 6.0 5.8 5.4 5.1 4.9 4.7  
ATP·Na2 0.1 M 509 509 509 509 509 510 511 512 514 4.6 
P-Creatine 0.5 M 290 290 290 290 290 290 290 290 290 2.6 
• Recheck pH and adjust accordingly. 
• Bring final volume to 9.5 ml each with ddH2O, NOT 10 ml.  
• When preparing the working reagent, add 10 μl CK solution to every 190 μl relaxing solution. 
• Store at -20 °C in aliquots of 1 ml for 2 months and -87 °C for longer periods. 
 
 
 
